var title_f13_27_13744="Secretory IgA J ch";
var content_f13_27_13744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F68546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F68546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Secretory IgA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Seipp R. Mucosal immunity and vaccines. The Science Creative Quarterly, August 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13744=[""].join("\n");
var outline_f13_27_13744=null;
var title_f13_27_13745="Intraocular foreign body";
var content_f13_27_13745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient who suffered penetrating eye injury with residual intraocular nail",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Clinical photo.",
"    <br>",
"     (B) CT scan of the orbit showing extent of intraocular penetration.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13745=[""].join("\n");
var outline_f13_27_13745=null;
var title_f13_27_13746="Osteonecrosis of hip";
var content_f13_27_13746=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79133%7ERHEUM%2F69304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79133%7ERHEUM%2F69304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteonecrosis of the femoral head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph of the pelvis and hips of a 41-year-old man who has received a cardiac transplant and who is on corticosteroids. There is stage III (moderately late) avascular necrosis of both femoral heads manifested by increased density within each femoral head but no collapse (arrows). The increased density reflects marrow infarcts with calcification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark Robbins, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteonecrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A plain film of the hip demonstrating features consistent with ischemic necrosis of the femoral head. These include lucent regions with associated sclerotic rims in the right femoral head (arrows), squared-off, straight margins, and mottled increased density due to destruction of the bony trabecula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13746=[""].join("\n");
var outline_f13_27_13746=null;
var title_f13_27_13747="Toxic epidermal necrolysis - abdomen";
var content_f13_27_13747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple bullae and large areas of desquamation are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13747=[""].join("\n");
var outline_f13_27_13747=null;
var title_f13_27_13748="Dronabinol: Patient drug information";
var content_f13_27_13748=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dronabinol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/49/30485?source=see_link\">",
"     see \"Dronabinol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/40/30340?source=see_link\">",
"     see \"Dronabinol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16116938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Marinol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F163505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Marinol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you eat more.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701990",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dronabinol, sesame oil, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have schizophrenia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take before lunch and dinner to help you eat more.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at a cool temperature of 46&deg;F to 59&deg;F (8&deg;C to 15&deg;C) or in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12403 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13748=[""].join("\n");
var outline_f13_27_13748=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16116938\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163505\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012286\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012285\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012290\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012291\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012293\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012288\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012289\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012294\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012295\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/49/30485?source=related_link\">",
"      Dronabinol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/40/30340?source=related_link\">",
"      Dronabinol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_27_13749="Cytarabine: Patient drug information";
var content_f13_27_13749=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cytarabine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     see \"Cytarabine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37655?source=see_link\">",
"     see \"Cytarabine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F155998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cytarabine Injection;",
"     </li>",
"     <li>",
"      Cytosar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701880",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cytarabine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May not be able to get pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695987",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein or into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3860602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given as a shot into a special port in the skull or spine for treatment of cancer in the CNS (central nervous system).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3431441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given in a hospital or doctor's office. If stored at home, follow how to store as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12350 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13749=[""].join("\n");
var outline_f13_27_13749=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026882\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026884\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026883\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026888\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026889\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026891\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026886\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026892\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026893\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=related_link\">",
"      Cytarabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37655?source=related_link\">",
"      Cytarabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_27_13750="Autofluorescence endoscopy for Barrett's esophagus";
var content_f13_27_13750=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autofluorescence endoscopy for Barrett's esophagus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/27/13750/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13750/contributors\">",
"     Jacques J Bergman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/27/13750/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13750/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/27/13750/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13750/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/27/13750/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barrett's esophagus (BE) is the most important risk factor for esophageal adenocarcinoma, the incidence of which has been rising rapidly over the past few decades. Standard endoscopic imaging provides little detail of the mucosal surface, making it impossible to distinguish specialized intestinal epithelium from gastric type metaplasia or to recognize dysplastic epithelium.",
"   </p>",
"   <p>",
"    Better imaging modalities have the potential to improve detection of Barrett's esophagus and surveillance for dysplasia and cancer. Many new endoscopic techniques continue to be developed including magnification endoscopy, chromoendoscopy, optical coherence tomography, narrow band imaging, and autofluorescence endoscopy, but none is used routinely in clinical practice.",
"   </p>",
"   <p>",
"    This topic review will summarize experience with autofluorescence endoscopy. General approaches to diagnosis and management of Barrett's esophagus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1161?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIGHT-TISSUE INTERACTION AND AUTOFLUORESCENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several interactions are possible when a photon of light (excitation light) comes into contact with tissue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The photon may be reflected immediately.",
"     </li>",
"     <li>",
"      It may pass through the tissue for a certain distance to be absorbed by chromophores (defined below) (",
"      <a class=\"graphic graphic_figure graphicRef72644 \" href=\"UTD.htm?15/16/15616\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A small proportion of the excitation light causes a light-tissue interaction resulting in a change in its wave-length, a phenomenon known as autofluorescence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reflection and absorption are the main light-tissue interactions that are relevant for conventional endoscopy. Barrett's esophagus has a reddish appearance since most of the red light is reflected while most of the green and blue light is absorbed by chromophores in the mucosa and submucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chromophores",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromophores absorb photons without emission of fluorescence. The chromophores can absorb both excitation and fluorescence light. The absorption depends strongly on the wavelength of the light and may significantly modify the in vivo autofluorescence spectrum observed at the tissue surface. The main chromophore in gastrointestinal tissues in the visible wavelength range (400 to 700 nm) is hemoglobin, in its oxygenated or deoxygenated form [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fluorophores",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluorophores are biological substances that emit fluorescent light (which has a long wavelength) when exposed to light of a short wavelength (usually ultraviolet or blue light). The most important fluorophores responsible for tissue autofluorescence include collagen, reduced-nicotinamide adenine dinucleotide (NADH), aromatic amino acids, and porphyrins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/1\">",
"     1",
"    </a>",
"    ]. Each group of fluorophores has characteristic ranges of optimal excitation and emission wavelengths, and the emission bandwidths of many different fluorophores are broad and overlapping [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/2\">",
"     2",
"    </a>",
"    ]. Although several studies have investigated the utility of tissue autofluorescence in BE, the most relevant fluorophores responsible for autofluorescence in BE are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autofluorescence for distinguishing tissue types",
"    </span>",
"    &nbsp;&mdash;&nbsp;The autofluorescence spectra of normal, metaplastic, and dysplastic tissues differ because of variation of the types, concentrations, and microdistribution of the constituent fluorophores and chromophores. However, the extent to which the differences can accurately distinguish among these epithelial states is incompletely understood (see below).",
"   </p>",
"   <p>",
"    No marked differences in the intensity and microdistribution of epithelial autofluorescence between non-dysplastic BE and high-grade intraepithelial neoplasia (HGIN) was observed in one report evaluating autofluorescence in ex-vivo specimens from patients with BE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/3\">",
"     3",
"    </a>",
"    ]. By contrast, autofluorescence is generally decreased in dysplastic BE when examined in-vivo. This suggests that differences in autofluorescence are not caused by specific changes in endogenous fluorophores within the epithelium but probably by alterations in tissue architecture and hemoglobin content that influence autofluorescence when seen in-vivo.",
"   </p>",
"   <p>",
"    The decreased autofluorescence seen in-vivo in patients with dysplastic BE is probably caused by three mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nuclei have little or no autofluorescence compared with cytoplasm, and dysplastic cells have an increase in the nuclear-to-cytoplasm ratio.",
"     </li>",
"     <li>",
"      Dysplasia may be accompanied by thickening of the mucosal layer, thereby preventing light from penetrating into the submucosal layer. Collagen, located in the submucosal layer is the dominant fluorophore in the visible (400-700 nm) wavelength range in the gastrointestinal tract. Thus increased mucosal thickness in early neoplastic lesions leads to an attenuation in submucosal tissue autofluorescence.",
"     </li>",
"     <li>",
"      An increase in the local concentration of tissue hemoglobin (especially in the mucosal layer) occurs during neoplastic transformation thereby attenuating autofluorescence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have suggested that findings on autofluorescence combined with other characteristics could help improve detection of tissue types. In one such report, early neoplasia in autofluorescence-positive areas of BE was independently associated with autofluorescence intensity, a distance of less than 1 cm from the gastric folds, and a different appearance on white-light endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     AUTOFLUORESCENCE SPECTROSCOPY AND ENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two in-vivo autofluorescence-based endoscopic techniques have been investigated for detecting early neoplasia in BE:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Light-induced fluorescence spectroscopy (LIFS)",
"     </li>",
"     <li>",
"      Autofluorescence endoscopy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Light-induced fluorescence spectroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In LIFS, a small light probe is passed through the working channel of an endoscope and brought into close contact with an area of interest. The light probe consists of a central delivery fiber (connected to a light source, which is often a laser) and multiple surrounding detector fibers for collection of the fluorescent light (connected to a spectrograph for depiction of the fluorescent spectrum).",
"   </p>",
"   <p>",
"    LIFS can accurately distinguish BE with high-grade intraepithelial neoplasia (HGIN) from nondysplastic BE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. However, an important drawback is that it only samples a small area of mucosa, making it impractical as a surveillance tool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Autofluorescence endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autofluorescence endoscopy incorporates a real-time wide-angle view that allows the endoscopist to switch back-and-forth between standard white light imaging and autofluorescence endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817109340\">",
"    <span class=\"h3\">",
"     Fiberoptic fluorescence endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first prototype fluorescence endoscopic imaging device (LIFE-II system, Xillix Technologies Corp, Richmond, BC, Canada) consists of a fiberoptic endoscope with an attached camera module that permits fast switching between white light endoscopy and light-induced fluorescence endoscopy (LIFE). The LIFE mode is excited through a metal halide light source with a blue light band pass filter (400 to 450 nm), and the system is equipped with two intensified charged coupled devices (CCDs) integrated in the camera module for detection of green (490 to 560 nm) and red (&gt;630 nm) tissue autofluorescence, together with an image processor for displaying the autofluorescence image on a monitor. A composite image is formed, with dysplastic lesions displayed as a brick-red color against a",
"    <span class=\"nowrap\">",
"     green/cyan",
"    </span>",
"    colored normal background (",
"    <a class=\"graphic graphic_picture graphicRef53968 \" href=\"UTD.htm?3/31/3573\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/9\">",
"     9",
"    </a>",
"    ]. However, some reports noted only occasional recognition of HGIN within BE using LIFE and found that BE itself can produce false-positive red fluorescence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultimately, randomized controlled trials were performed comparing fiberoptic LIFE with standard white light video endoscopy (SVE) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One randomized trial compared a fiberoptic LIFE system with SVE in 187 patients with BE [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/13\">",
"       13",
"      </a>",
"      ]. In the first phase of the trial, patients were assigned to be examined with LIFE or SVE. In this phase, LIFE did not show a significantly higher yield for detecting early neoplasia compared with SVE (12 versus 5 percent, p=0.40). In addition, 11 of 19 lesions (58 percent) that contained early neoplasia were not suspicious on LIFE and were only detected on random biopsies.",
"      <br/>",
"      <br/>",
"      In the second phase of the trial, patients underwent a second endoscopy with LIFE when they had previously undergone SVE and vice versa. Approximately one-third of the group failed to undergo a second endoscopy due to treatment of early neoplasia detected on the first endoscopy, declination of further participation, or noncompliance with the study protocol. Again, no significant difference in detection of early neoplasia was found between the fluorescence endoscopy and SVE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another randomized cross-over trial compared LIFE with SVE for the detection of early neoplasia in BE [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/12\">",
"       12",
"      </a>",
"      ]. Forty-seven patients with known BE were randomly assigned to undergo either LIFE or SVE as the first procedure, followed by cross-over to the other technique after four to six weeks. Each procedure was performed by one of two experienced endoscopists who were randomly allocated to either LIFE or SVE for each patient and were blinded to the findings of the other examination.",
"      <br/>",
"      <br/>",
"      After both endoscopies, 5 patients showed no dysplasia, 10 were indefinite for dysplasia, 19 had low-grade intraepithelial neoplasia (LGIN), and 13 had HGIN or early carcinoma. Targeted biopsies taken with both LIFE and SVE each detected 8 of 13 patients (62 percent) with histologically confirmed",
"      <span class=\"nowrap\">",
"       HGIN/early",
"      </span>",
"      carcinoma. When random biopsies were also considered, LIFE and SVE detected 69 and 85 percent of",
"      <span class=\"nowrap\">",
"       HGIN/early",
"      </span>",
"      carcinoma, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These initial trials suggest that the prototype devices used thus far do not provide additional value in the detection of early neoplasia in BE. There are three possible explanations for this:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, the white light images from the fiberoptic fluorescence endoscopes were poorer in quality than with current video endoscopes, in part because of the use of fiber optics. As a result, subtle topographical mucosal features may have been overlooked (",
"      <a class=\"graphic graphic_picture graphicRef61618 \" href=\"UTD.htm?17/53/18257\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Second, the fluorescence endoscopy imaging systems used have relied on either total autofluorescence or the combination of detecting green (490 to 560 nm) and red (&gt;630 nm) autofluorescence. These algorithms may not be optimized for BE. Further refinements of emission bandwidths specifically selected for autofluorescence imaging in BE are in progress.",
"     </li>",
"     <li>",
"      Third, the endoscopists were highly experienced, so the impact of the additional information obtained by LIFE used adjunctively with SVE may be less than for less experienced individuals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1817109381\">",
"    <span class=\"h3\">",
"     Video autofluorescence imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video autofluorescence imaging (AFI) addresses most of the limitations of fiberoptic fluorescence endoscopy. AFI incorporates a high-resolution video endoscope and a fluorescence imaging modality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/14\">",
"     14",
"    </a>",
"    ]. A prototype system was developed that is based on a light source with sequential red-green-and-blue (RGB) illumination. White light from a Xenon lamp is passed through a rotary RGB filter that separates the white light into the colors red, green, and blue that are used to sequentially illuminate the mucosa. The red, green, and blue reflected light is detected separately by a monochromatic CCD placed at the tip of the endoscope, and the three images are integrated into a single high-quality color image by the video processor that is synchronized with the rotation speed of the RGB-filter.",
"   </p>",
"   <p>",
"    The system uses a special high-resolution video endoscope (GIFQ240FY, Olympus, Tokyo, Japan) that has two high-quality CCDs at its tip: one for white light endoscopy as explained above and a second one for autofluorescence imaging. In the AFI-mode, the autofluorescence image is composed of three components: (1) total autofluorescence after blue light excitation, (2) green reflectance, and (3) red reflectance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This system produces excellent white light images and high-quality autofluorescence images in contrast to earlier prototypes that used fiber optic endoscopes (",
"    <a class=\"graphic graphic_picture graphicRef66867 \" href=\"UTD.htm?36/31/37360\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/14\">",
"     14",
"    </a>",
"    ]. Non-dysplastic BE appears green on AFI, whereas suspicious areas appear",
"    <span class=\"nowrap\">",
"     blue/violet",
"    </span>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef54566 \" href=\"UTD.htm?22/31/23025\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The first uncontrolled studies of AFI in patients with BE showed promising results for improving the detection of areas with high-grade intraepithelial neoplasia (HGIN) and early carcinoma in high-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. An important drawback of AFI in these studies was high false-positive rates, ranging between 40 and 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. However, studies suggest that by combining AFI with another state-of-the-art imaging technique (eg, narrow band imaging), this false positive rate can be reduced to 10 to 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=see_link\">",
"     \"Narrow band imaging in Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An endoscopy system is commercially available that incorporates high-resolution white light endoscopy, AFI, and narrow band imaging: endoscopic tri-modal imaging (ETMI) (Lucera, Olympus, Tokyo, Japan). An international multicenter uncontrolled feasibility study with this system showed that ETMI increased the targeted detection of HGIN and early carcinoma from 53 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, two multicenter randomized cross-over studies were performed comparing ETMI with SVE for the detection of early neoplasia in two different settings: patients with inconspicuous early neoplasia referred to a tertiary referral center for endoscopic treatment, and patients with confirmed LGIN undergoing surveillance in a general practice setting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In both studies, patients were assigned to undergo ETMI or SVE first and to subsequently undergo a second procedure with the other technique a few weeks later. White light endoscopy and AFI were used for the detection of suspicious lesions. Biopsy samples were taken from suspicious areas and at random.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tertiary referral setting: In 87 patients who underwent both procedures, ETMI detected significantly more patients with suspicious areas containing HGIN or early carcinoma compared with SVE (36 versus",
"      <em>",
"      </em>",
"      24 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/17\">",
"       17",
"      </a>",
"      ]. When comparing overall detection, including targeted detection and random sampling, there was a trend toward ETMI detecting more patients with HGIN and early carcinoma (46 versus",
"      <em>",
"      </em>",
"      40 patients), but the difference did not reach statistical significance [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      General practice setting: In 99 patients, ETMI detected significantly more dysplastic lesions (including LGIN) compared with SVE (49 versus",
"      <em>",
"      </em>",
"      29 lesions), but it did not detect significantly more lesions containing HGIN or early carcinoma (16 versus",
"      <em>",
"      </em>",
"      14 lesions). In addition, when analyzed per patient (instead of per lesion), there was no significant difference in the overall detection of dysplasia between ETMI and SVE (60 versus 54 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13750/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    From these results, we conclude that AFI currently does not have a role in the routine detection of HGIN and early carcinoma in BE patients, but it could be a useful guide for endoscopic therapy in these patients. Studies elucidating the impact of additional AFI detected lesions on endoscopic treatment of early Barrett's neoplasia should therefore be undertaken. Overall, these results indicate that AFI and ETMI are not ready to replace the use of random biopsy protocols for the detection of early neoplasia in BE patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/29/13778?source=see_link\">",
"       \"Patient information: Barrett's esophagus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/39/2676?source=see_link\">",
"       \"Patient information: Barrett's esophagus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of autofluorescence imaging in Barrett's esophagus has not yet been defined. Autofluorescence represents one of several new approaches being evaluated in the hope of improving detection and surveillance of Barrett's esophagus. Autofluorescence may improve the detection of early neoplasia in Barrett's esophagus by drawing the endoscopist's attention abnormal areas, after which additional imaging techniques or targeted biopsies can be used. Additional studies are needed to better understand whether this benefit can be achieved and the impact it has on the care of patients with Barrett's esophagus.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/1\">",
"      Kara M, DaCosta RS, Wilson BC, et al. Autofluorescence-based detection of early neoplasia in patients with Barrett's esophagus. Dig Dis 2004; 22:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/2\">",
"      Dacosta RS, Wilson BC, Marcon NE. New optical technologies for earlier endoscopic diagnosis of premalignant gastrointestinal lesions. J Gastroenterol Hepatol 2002; 17 Suppl:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/3\">",
"      Kara MA, Dacosta RS, Streutker CJ, et al. Characterization of Tissue Autofluorescence (AF) In Non-dysplastic (NDBE) And Dysplastic Barrett Esophagus (BE) By Confocal Fluorescence Microscopy (CFM) (abstract). Gastroenterology 2004; 126:A50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/4\">",
"      Curvers WL, Singh R, Wallace MB, et al. Identification of predictive factors for early neoplasia in Barrett's esophagus after autofluorescence imaging: a stepwise multicenter structured assessment. Gastrointest Endosc 2009; 70:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/5\">",
"      Vo-Dinh T, Panjehpour M, Overholt BF. Laser-induced fluorescence for esophageal cancer and dysplasia diagnosis. Ann N Y Acad Sci 1998; 838:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/6\">",
"      Georgakoudi I, Jacobson BC, Van Dam J, et al. Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. Gastroenterology 2001; 120:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/7\">",
"      Bourg-Heckly G, Blais J, Padilla JJ, et al. Endoscopic ultraviolet-induced autofluorescence spectroscopy of the esophagus: tissue characterization and potential for early cancer diagnosis. Endoscopy 2000; 32:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/8\">",
"      Panjehpour M, Overholt BF, Vo-Dinh T, et al. Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. Gastroenterology 1996; 111:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/9\">",
"      Haringsma J, Tytgat GN, Yano H, et al. Autofluorescence endoscopy: feasibility of detection of GI neoplasms unapparent to white light endoscopy with an evolving technology. Gastrointest Endosc 2001; 53:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/10\">",
"      Wong Kee Song LM, Marcon NE. Fluorescence and Raman spectroscopy. Gastrointest Endosc Clin N Am 2003; 13:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/11\">",
"      Egger K, Werner M, Meining A, et al. Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques. Gut 2003; 52:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/12\">",
"      Kara MA, Smits ME, Rosmolen WD, et al. A randomized crossover study comparing light-induced fluorescence endoscopy with standard videoendoscopy for the detection of early neoplasia in Barrett's esophagus. Gastrointest Endosc 2005; 61:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/13\">",
"      Borovicka J, Fischer J, Neuweiler J, et al. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy. Endoscopy 2006; 38:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/14\">",
"      Kara MA, Peters FP, Ten Kate FJ, et al. Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett's esophagus. Gastrointest Endosc 2005; 61:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/15\">",
"      Kara MA, Peters FP, Fockens P, et al. Endoscopic video-autofluorescence imaging followed by narrow band imaging for detecting early neoplasia in Barrett's esophagus. Gastrointest Endosc 2006; 64:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/16\">",
"      Curvers WL, Singh R, Song LM, et al. Endoscopic tri-modal imaging for detection of early neoplasia in Barrett's oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut 2008; 57:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/17\">",
"      Curvers WL, Herrero LA, Wallace MB, et al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology 2010; 139:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13750/abstract/18\">",
"      Curvers WL, van Vilsteren FG, Baak LC, et al. Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett's neoplasia: a multicenter, randomized, crossover study in general practice. Gastrointest Endosc 2011; 73:195.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2647 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13750=[""].join("\n");
var outline_f13_27_13750=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIGHT-TISSUE INTERACTION AND AUTOFLUORESCENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chromophores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fluorophores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autofluorescence for distinguishing tissue types",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AUTOFLUORESCENCE SPECTROSCOPY AND ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Light-induced fluorescence spectroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Autofluorescence endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1817109340\">",
"      - Fiberoptic fluorescence endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1817109381\">",
"      - Video autofluorescence imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2647\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2647|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/16/15616\" title=\"figure 1\">",
"      Principles of autofluorescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2647|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/31/3573\" title=\"picture 1\">",
"      Xillix Barretts high grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/53/18257\" title=\"picture 2\">",
"      Xillix image white light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/31/37360\" title=\"picture 3\">",
"      Barretts high-grade AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/31/23025\" title=\"picture 4\">",
"      Esoph cancer autofluorescence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1161?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=related_link\">",
"      Narrow band imaging in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/39/2676?source=related_link\">",
"      Patient information: Barrett's esophagus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/29/13778?source=related_link\">",
"      Patient information: Barrett's esophagus (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_27_13751="Laboratory diagnosis of coccidioidomycosis";
var content_f13_27_13751=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laboratory diagnosis of coccidioidomycosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/27/13751/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13751/contributors\">",
"     John N Galgiani, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/27/13751/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13751/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/27/13751/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13751/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/27/13751/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccidioides spp (C. immitis and C. posadasii), fungi endemic in desert regions of the southwestern United States and Central and South America, cause coccidioidomycosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link&amp;anchor=H2#H2\">",
"     \"Primary coccidioidal infection\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary coccidioidal infection\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coccidioidomycosis has protean manifestations and is frequently unrecognized, especially in travelers to endemic areas who return to locations where the disease is not typically encountered. Without specific laboratory tests, it is generally not possible to differentiate coccidioidal infections from numerous other illnesses. This is especially true for the initial respiratory illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several routine tests are commonly abnormal, especially with early coccidioidal pneumonia, but all are nonspecific. These include a slight increase in the peripheral white blood cell count, peripheral eosinophilia, and an elevated erythrocyte sedimentation rate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/2\">",
"     2",
"    </a>",
"    ]. Similarly, chest radiographs or other imaging procedures may also reveal abnormalities. Although occasionally suggestive of the precise diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/3\">",
"     3",
"    </a>",
"    ], confirmatory tests are nearly always needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conventional approaches to diagnosing coccidioidomycosis involve identification or recovery of Coccidioides spp from clinical specimens and detection of specific anti-coccidioidal antibodies in serum or other body fluids.",
"   </p>",
"   <p>",
"    The laboratory diagnosis of coccidioidomycosis will be reviewed here. The epidemiology, clinical manifestations, and treatment of coccidioidomycosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17271?source=see_link\">",
"     \"Coccidioidal meningitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=see_link\">",
"     \"Coccidioidomycosis in compromised hosts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39734?source=see_link\">",
"     \"Management of pulmonary sequelae and complications of coccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=see_link\">",
"     \"Manifestations and treatment of extrapulmonary coccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H809390652\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most ambulatory patients who are suspected to have coccidioidomycosis are evaluated with serologic testing. Although cultures in outpatients might be useful, many clinicians do not consider this option, and they can be difficult to obtain because patients do not typically have a productive cough. Cultures are more often obtained in patients requiring hospitalization. Many clinical laboratories will have a single coccidioidal antibody test available. If all options for serologic testing are available, enzyme-linked immunoassays for IgM and IgG are probably the most sensitive screening tests and should therefore be ordered first. Immunodiffusion tests are less sensitive but more specific. Quantitative complement fixing antibodies or immunodiffusion tests are the most appropriate tests for monitoring response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RECOVERY OF COCCIDIOIDES SPP FROM CLINICAL SPECIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since Coccidioides spp are never normal flora, identifying this fungus in respiratory secretions, tissue, or other patient specimens is definitive evidence of a coccidioidal infection. This can be accomplished by either identifying the organism by direct examination or by growing it in from fungal cultures.&nbsp;Coccidioides spp will also grow on routine bacterial media, but the plates must be held longer (usually one week) than is routinely done to isolate bacteria. Despite the specificity of detecting Coccidioides spp from clinical specimens, cultures are not routinely obtained in the majority of coccidioidal infections. Whether this should be recommended for standard practice is a point of conjecture. On the one hand, obtaining fungal cultures in many office settings may be logistically difficult, and specimens that yield Coccidioides spp in culture pose a certain degree of risk to laboratory personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, because Coccidioides spp are listed by the CDC as select agents of bioterrorism (",
"    <a class=\"external\" href=\"file://www.cdc.gov/od/sap\">",
"     www.cdc.gov/od/sap",
"    </a>",
"    ), clinical laboratories that handle these fungi must follow extensive and documented security practices.",
"   </p>",
"   <p>",
"    On the other hand, positive cultures may be the earliest and, in some instances, the only means of diagnosis. As a general rule, seeking to isolate Coccidioides spp becomes increasingly important for patients with more debilitating or widespread infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=see_link\">",
"     \"Manifestations and treatment of extrapulmonary coccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17271?source=see_link\">",
"     \"Coccidioidal meningitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=see_link\">",
"     \"Coccidioidomycosis in compromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Staining characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common morphologic form of Coccidioides spp seen in clinical specimens during infection are spherules. These are often sufficiently large (20 to 70 microns) enough to be seen with magnification of 100- to 400-fold. However, Gram stain of respiratory tract specimens will miss these structures, since spherules do not take up the stain. The simplest method to detect spherules is to make a \"wet preparation\" using saline or potassium hydroxide solution. Calcofluor staining may also improve direct detection of spherules [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/5\">",
"     5",
"    </a>",
"    ]. Bronchoalveolar washings are often analyzed with Papanicolaou staining, which also reacts with spherules [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For tissue, hematoxylin and eosin staining will usually be sufficient to detect spherules, although occasionally special stains such as periodic acid Schiff or Grocott- or Gomori-methenamine silver will be needed (",
"    <a class=\"graphic graphic_picture graphicRef75250 graphicRef55301 graphicRef68068 \" href=\"UTD.htm?39/36/40522\">",
"     picture 1A-C",
"    </a>",
"    ). However, spherules generally number less than 1 per 10 high-power fields in most specimens; thus, an extensive examination of such preparations will improve detection. Occasionally, mycelial elements are present in coccidioidal lesions, but these cannot be distinguished from other fungal species on morphologic characteristics. In one report, hyphal forms were demonstrated in the cerebrospinal fluid (CSF) or brain tissue from five patients with plastic devices present in the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/7\">",
"     7",
"    </a>",
"    ]. Mycelia were also evident in pulmonary cavities and in association with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Techniques are now available to identify Coccidioides in fixed tissue by PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccidioides spp are capable of growing on nearly any laboratory media, and therefore even routine cultures for bacterial isolation can be used. Growth usually is evident within the first week, although prior receipt of antifungal agents can delay isolation. Most strains of Coccidioides spp are non-pigmented. However, this is not always the case, and laboratory personnel should handle any culture in which hyphal growth becomes evident with appropriate biocontainment procedures since exposure in the laboratory setting can lead to infection in laboratory staff [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, when coccidioidomycosis is suspected clinically, the clinician caring for the patient should alert the microbiology laboratory.",
"   </p>",
"   <p>",
"    In order to determine if an isolated fungus is within the Coccidioides genus, additional testing is necessary. In the past, the most common approach was to prepare a formalin extract of the fungus and determine if it contained a \"Coccidioides-specific\" antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Although extremely reliable, this approach takes two or more weeks to complete. A more rapid procedure is now available as a commercial kit (Genprobe, San Diego CA), which detects a C. immitis-specific DNA sequence. This has also been highly reliable and takes less than one day to complete [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some reference laboratories offer molecular speciation, at present there are no commercially available tests to distinguish between C. immitis and C. posadasii [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/16\">",
"     16",
"    </a>",
"    ]. C. posadasii grows more readily at elevated temperatures than C. immitis, and this difference has been exploited to provide a relatively accurate means to determine species in a general clinical laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DETECTION OF ANTI-COCCIDIOIDAL ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients exposed to Coccidioides spp develop symptoms of their acute illness 7 to 21 days later. Concurrently, antibodies develop against specific coccidioidal antigens in many, if not most, patients. When detected, anticoccidioidal antibodies are quite specific. However, the ability to detect these antibodies may lag behind the onset of illness by several weeks or even months, particularly in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. For this reason, the absence of detectable anticoccidioidal antibodies does not exclude the diagnosis of coccidioidomycosis, especially early in the course of the clinical illness.",
"   </p>",
"   <p>",
"    When antibodies are present, the concentrations decrease to undetectable levels during the course of illness for most patients who resolve their infection. Thus, patients who demonstrate measurable anticoccidioidal antibodies are likely to have a recent illness or one that continues to be active. Commercial immunodiffusion kits that measure IgM and IgG antibodies directed against the organism are the most common type of serologic test ordered. Immunodiffusion kits that detect tube precipitin-type antibodies and complement fixing antibodies are available. Within these general principles, the interpretation of the specific serologic tests varies as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunodiffusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunodiffusion kits for both IgM and IgG antibodies are in common use. The clinician may need to contact the reporting laboratory for further clarification if test results are reported simply as a positive or negative immunodiffusion result, which occurs frequently.",
"   </p>",
"   <p>",
"    Although the immunodiffusion test for IgM antibodies is normally done on undiluted sera, its sensitivity can be increased by concentrating the sera from two- to eightfold [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunodiffusion tests, when they are positive, are the most specific assays. If the immunodiffusion test is qualitatively positive, additional testing by the conventional CF test or a quantitative immunodiffusion test should be carried out. If either of these tests is positive, no additional testing is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tube precipitin-type antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the two original methods for detecting anticoccidioidal antibodies was to demonstrate the formation of an antigen-antibody precipitin when an extract of C. immitis was mixed with serum from an infected patient [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/22\">",
"     22",
"    </a>",
"    ]. These antibodies are directed against carbohydrate antigens of the fungal cell wall and develop relatively early during infection. Up to 90 percent of patients will have tube precipitin-type antibodies detected at some time within the first three weeks of symptoms. For patients with a self-limited illness, these antibodies decline to less than 5 percent within seven months.",
"   </p>",
"   <p>",
"    The tube precipitin assay is considered to be an \"IgM test\" because IgM antibodies are large and most capable of generating a precipitin reaction and because these reactions are detected early after the onset of infection.",
"   </p>",
"   <p>",
"    Tube precipitin-type antibody testing has been largely supplanted by a commercial immunodiffusion kit that measures the same antigen and accurately parallels the results of the original assay [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/13,23\">",
"     13,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complement fixing antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other original method for detecting coccidioidal antibodies is a complement fixation (CF) assay. This test is based upon the depletion of complement that results after antibodies in a specimen from an infected patient form an immune complex when mixed with a coccidioidal antigen. The complement depletion is assessed by the failure of tanned red blood cells to lyse when added to the mixture; these cells are normally lysed in the presence of complement. This CF assay is often referred to as the \"IgG test\" since IgG is the immunoglobulin class usually involved in such immune complexes. Although the coccidioidal antigen used in this procedure is a complex extract of C. immitis, it is now known that the antigen involved in this reaction is a chitinase, a protein enzyme important for the structure of the fungal cell wall [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Anti-chitinase antibodies responsible for the CF reaction are also responsible for the immunodiffusion IgG reaction referred to above.",
"   </p>",
"   <p>",
"    In early coccidioidal infections, CF antibodies are detected somewhat later and for longer periods than tube precipitin-type antibodies. CF-type antibodies can be detected in body fluids other than serum, and their detection in the CSF is an especially important aid to the diagnosis of coccidioidal meningitis. Antibody concentration is determined by assaying twofold serial dilutions of patient specimens for complement consumption. As a general rule, the greater the dilution that still results in complement consumption, the more likely the patient has extensive infection. Because the exact end-point result in relation to actual antibody concentration is difficult to standardize among laboratories, relative changes in results from the same laboratory may be more helpful in gauging whether a patient's infection is worsening (increasing titers) or improving (decreasing titers). Thus, serial determinations of CF-type antibodies have prognostic as well as diagnostic value.",
"   </p>",
"   <p>",
"    Although the original assay for CF-type antibodies continues to be used routinely by some reference laboratories, a commercial immunodiffusion kit can mimic the qualitative result of this reference procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Enzyme-linked immunoassays",
"    </span>",
"    &nbsp;&mdash;&nbsp;An enzyme-linked immunoassay (EIA) for coccidioidal antibodies is available commercially. Since specific antibodies are detected by reagents for different immunoglobulin classes, results from these tests are specific for IgM or IgG antibodies. Positive EIA results are highly sensitive for coccidioidal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/18\">",
"     18",
"    </a>",
"    ]. In one study of 160 serum and 66 CSF specimens tested by CF, tube precipitin, and EIA, the EIA had a sensitivity, specificity, and positive and negative predictive values of 100, 98, 96, and 100 percent, respectively, compared with CF [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enzyme-linked immunoassays (EIA) for IgM and IgG are more sensitive than immunodiffusion tests but may be less specific. When immunodiffusion and EIA test results are compared using panels of sera from patients with early coccidioidal infections, there are significantly more specimens positive by EIA than by immunodiffusion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]. Since there is frequently no independent confirmation of infection by culture in such patients, uncertainty surrounds the question of how to interpret positive EIA tests that are not confirmed by immunodiffusion. They are likely truly positive for patients when subsequent sera become immunodiffusion positive, but this only becomes clear with hindsight and may not occur for all patients. IgM EIA has been particularly prone to false-positive in the experience of some, but not all, laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EIA can be used as a screening test with immunodiffusion tests conducted only if the EIA is positive. Alternatively, EIA can be ordered if the immunodiffusion tests are negative when the clinical suspicion for coccidioidal infection remains high.",
"   </p>",
"   <p>",
"    Given these various considerations, a positive EIA might be viewed as supportive of a diagnosis of coccidioidomycosis when the clinical manifestations are consistent with this diagnosis. However, this may provide insufficient confidence in severely ill patients, in which case further evaluation, such as invasive procedures for fungal cultures or histology, may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Latex tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A latex test for coccidioidal antibodies is also available from commercial sources. Latex tests are attractive because of their ease of use and rapidity of obtaining a result. However, for detecting anticoccidioidal antibodies, the latex tests have thus far appeared to have a significant number of false-positive reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/28\">",
"     28",
"    </a>",
"    ]. For this reason, a positive latex test is not as reliable as any of the other tests described in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANTIGEN DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antigen detection methods are well established for diagnosing histoplasmosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been observed that some patients with severe coccidioidomycosis exhibit false-positive results with the Histoplasma urinary antigen assay [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/29\">",
"     29",
"    </a>",
"    ]. In response to this observation, an assay that detects coccidioidal antigen in the urine has been developed and was found to have a sensitivity of 71 percent among patients with severe coccidioidomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/30\">",
"     30",
"    </a>",
"    ]. In patients in whom coccidioidal serologies are negative, using this commercially available antigen test should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SKIN TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who become infected with Coccidioides spp develop dermal hypersensitivity to coccidioidal antigens as manifested by induration to skin testing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/31\">",
"     31",
"    </a>",
"    ]. For this reason, it is recommended by some to use skin testing as a diagnostic screening test. One drawback to this approach is that dermal hypersensitivity remains present for life and a reactive skin test may reflect infection in the distant past rather than the patient's current illness. Another problem is that occasional patients with the more extensive complications of coccidioidomycosis may be anergic; in these cases, a negative skin test could conceivably delay the correct diagnosis.",
"   </p>",
"   <p>",
"    Skin testing can be used for epidemiologic purposes. As an example, a study was performed in a city in northern Mexico to assess the prevalence of exposure to Coccidioides and risk factors for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13751/abstract/32\">",
"     32",
"    </a>",
"    ]. Among 1653 skin tests placed, 40 percent were positive.",
"   </p>",
"   <p>",
"    The skin testing reagents, coccidioidin or spherulin, are not commercially available currently in the United States, and thus, this test cannot be used for the diagnosis of individual patients or epidemiologic determinations. However, a company has applied to the US Food and Drug Administration for approval to make a reformulated skin testing reagent (replacing mercury-containing preservative with phenol).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/19/13617?source=see_link\">",
"       \"Patient information: Valley Fever (coccidioidomycosis) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific tests must be performed to make a diagnosis of coccidioidomycosis, since the illness has protean manifestations and cannot be distinguished from a variety of other infections on clinical grounds alone. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most ambulatory patients who are suspected to have coccidioidomycosis are evaluated with serologic testing. Although cultures in outpatients might be useful, many clinicians do not consider this option, and they can be difficult to obtain because patients do not typically have a productive cough. Cultures are more often obtained in patients requiring hospitalization. Many clinical laboratories will have a single coccidioidal antibody test available. If all options for serologic testing are available, enzyme-linked immunoassays for IgM and IgG are probably the most sensitive screening tests and should therefore be ordered first. Immunodiffusion tests are less sensitive but more specific. Quantitative complement fixing antibodies or immunodiffusion tests are the most appropriate tests for monitoring response to treatment. (See",
"      <a class=\"local\" href=\"#H809390652\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since Coccidioides spp are never normal flora, identifying this fungus in respiratory secretions, tissue, or other patient specimens is definitive evidence of a coccidioidal infection. This can be accomplished by either identifying the organism by direct examination or by growing it in culture. While frequently resorted to in only the most severe infections, it is always a useful approach when feasible. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Recovery of Coccidioides spp from clinical specimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunodiffusion tests, when they are positive, are the most specific serologic assays. If the immunodiffusion test is qualitatively positive, additional testing by the conventional CF test or a quantitative immunodiffusion test should be carried out. If either of these tests is positive, no additional testing is needed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Detection of anti-coccidioidal antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enzyme-linked immunoassays (EIA) for IgM and IgG are more sensitive than immunodiffusion tests but may be less specific. EIA can be used as a screening test with immunodiffusion tests conducted only if the EIA is positive. Alternatively, they can be ordered if the immunodiffusion tests are negative when the clinical suspicion for coccidioidal infection remains high. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunodiffusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Latex tests are easy to perform but have a higher rate of false positives than EIA. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Latex tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Detection of coccidioidal antigen may be diagnostically useful where antibodies are negative or as an additional surrogate marker of fungal burden where disease is extensive. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antigen detection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/1\">",
"      Kim MM, Blair JE, Carey EJ, et al. Coccidioidal pneumonia, Phoenix, Arizona, USA, 2000-2004. Emerg Infect Dis 2009; 15:397.",
"     </a>",
"    </li>",
"    <li>",
"     Lundergan, LL, Kerrick, SS, Galgiani, JN. Coccidioidomycosis at a university outpatient clinic: A clinical description. In: Coccidioidomycosis: Proceedings of the Fourth International Conference, Einstein, HE, Catanzaro, A, (Eds), National Foundation for Infectious Diseases, Washington 1985. p.47.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/3\">",
"      Yozwiak ML, Lundergan LL, Kerrick SS, Galgiani JN. Symptoms and routine laboratory abnormalities associated with coccidioidomycosis. West J Med 1988; 149:419.",
"     </a>",
"    </li>",
"    <li>",
"     Pappagianis, D. Coccidioidomycosis (San Joaquin or Valley Fever). In: Occupational Mycoses, DiSalvo, A, (Ed), Lea and Febiger, Philadelphia, 1983. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/5\">",
"      Monheit JE, Cowan DF, Moore DG. Rapid detection of fungi in tissues using calcofluor white and fluorescence microscopy. Arch Pathol Lab Med 1984; 108:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/6\">",
"      Sobonya RE, Barbee RA, Wiens J, Trego D. Detection of fungi and other pathogens in immunocompromised patients by bronchoalveolar lavage in an area endemic for coccidioidomycosis. Chest 1990; 97:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/7\">",
"      Hagman HM, Madnick EG, D'Agostino AN, et al. Hyphal forms in the central nervous system of patients with coccidioidomycosis. Clin Infect Dis 2000; 30:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/8\">",
"      Mu&ntilde;oz-Hern&aacute;ndez B, Mart&iacute;nez-Rivera MA, Palma Cort&eacute;s G, et al. Mycelial forms of Coccidioides spp. in the parasitic phase associated to pulmonary coccidioidomycosis with type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis 2008; 27:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/9\">",
"      Nicolasora N, Cinti SK, Riddell Iv J, Kauffman CA. Photo quiz. A 53-year-old man with a large air bubble in his chest. Clin Infect Dis 2008; 47:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/10\">",
"      Bialek R. Amplification of coccidioidal DNA in clinical specimens by PCR. J Clin Microbiol 2005; 43:1492; author reply 1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/11\">",
"      Bialek R, Gonz&aacute;lez GM, Begerow D, Zelck UE. Coccidioidomycosis and blastomycosis: advances in molecular diagnosis. FEMS Immunol Med Microbiol 2005; 45:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/12\">",
"      Stevens DA, Clemons KV, Levine HB, et al. Expert opinion: what to do when there is Coccidioides exposure in a laboratory. Clin Infect Dis 2009; 49:919.",
"     </a>",
"    </li>",
"    <li>",
"     Huppert, M, Bailey, JW, Chitjian, P. Immunodiffusion as a substitute for complement fixation and tube precipitin tests in coccidioidomycosis. In: Coccidioidomycosis. The Second Symposium on Coccidioidomycosis, Ajello, L, (Ed), University of Arizona Press, Tucson 1967. p.221.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/14\">",
"      Huppert M, Sun SH, Rice EH. Specificity of exoantigens for identifying cultures of Coccidioides immitis. J Clin Microbiol 1978; 8:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/15\">",
"      Sandhu GS, Kline BC, Stockman L, Roberts GD. Molecular probes for diagnosis of fungal infections. J Clin Microbiol 1995; 33:2913.",
"     </a>",
"    </li>",
"    <li>",
"     Fisher, MC, Koenig, GL, White, Taylor, JT. Molecular and phenotypic description of Coccidioides Posadasii sp nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia 2002; 94:73. Available at: file://www.mycologia.org/cgi/reprint/94/1/73.pdf (Accessed May 15, 2008).",
"    </li>",
"    <li>",
"     Barker, BM, Wendel, C, Galgiani, JN, Orbach, MJ. Thermotolerance differences between species of coccidioides allow development of an assay for species delineation. Mycopathologia 2010; [In press].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/18\">",
"      Wieden MA, Lundergan LL, Blum J, et al. Detection of coccidioidal antibodies by 33-kDa spherule antigen, Coccidioides EIA, and standard serologic tests in sera from patients evaluated for coccidioidomycosis. J Infect Dis 1996; 173:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/19\">",
"      Blair JE, Coakley B, Santelli AC, et al. Serologic testing for symptomatic coccidioidomycosis in immunocompetent and immunosuppressed hosts. Mycopathologia 2006; 162:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/20\">",
"      Pappagianis D, Zimmer BL. Serology of coccidioidomycosis. Clin Microbiol Rev 1990; 3:247.",
"     </a>",
"    </li>",
"    <li>",
"     Oubsuntia, V, Bogul, N, Lancaster, M. Utility of positive enzyme immunoassay results for detection of Coccidioides specific IGM. Proceedings of the Fifty-fourth Annual Coccidioidomycosis Study Group. In press.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/22\">",
"      SMITH CE, SAITO MT, SIMONS SA. Pattern of 39,500 serologic tests in coccidioidomycosis. J Am Med Assoc 1956; 160:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/23\">",
"      Huppert, M, Bailey, JW. Immunodiffusion as a screening test for coccidioidomycosis serology. Sab 1963; 2:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/24\">",
"      Johnson SM, Pappagianis D. The coccidioidal complement fixation and immunodiffusion-complement fixation antigen is a chitinase. Infect Immun 1992; 60:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/25\">",
"      Yang MC, Magee DM, Cox RA. Mapping of a Coccidioides immitis-specific epitope that reacts with complement-fixing antibody. Infect Immun 1997; 65:4068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/26\">",
"      Zartarian M, Peterson EM, de la Maza LM. Detection of antibodies to Coccidioides immitis by enzyme immunoassay. Am J Clin Pathol 1997; 107:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/27\">",
"      Blair JE, Currier JT. Significance of isolated positive IgM serologic results by enzyme immunoassay for coccidioidomycosis. Mycopathologia 2008; 166:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/28\">",
"      Huppert M, Peterson ET, Sun SH, et al. Evaluation of a latex particle agglutination test for coccidioidomycosis. Am J Clin Pathol 1968; 49:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/29\">",
"      Kuberski T, Myers R, Wheat LJ, et al. Diagnosis of coccidioidomycosis by antigen detection using cross-reaction with a Histoplasma antigen. Clin Infect Dis 2007; 44:e50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/30\">",
"      Durkin M, Connolly P, Kuberski T, et al. Diagnosis of coccidioidomycosis with use of the Coccidioides antigen enzyme immunoassay. Clin Infect Dis 2008; 47:e69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/31\">",
"      SMITH CE, WHITING EG. The use of coccidioidin. Am Rev Tuberc 1948; 57:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13751/abstract/32\">",
"      Padua y Gabriel A, Mart&iacute;nez-Ordaz VA, Velasco-Rodreguez VM, et al. Prevalence of skin reactivity to coccidioidin and associated risks factors in subjects living in a northern city of Mexico. Arch Med Res 1999; 30:388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2420 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13751=[""].join("\n");
var outline_f13_27_13751=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H809390652\">",
"      APPROACH TO DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RECOVERY OF COCCIDIOIDES SPP FROM CLINICAL SPECIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Staining characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DETECTION OF ANTI-COCCIDIOIDAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunodiffusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tube precipitin-type antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complement fixing antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Enzyme-linked immunoassays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Latex tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANTIGEN DETECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SKIN TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2420\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2420|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/21/4438\" title=\"picture 1A\">",
"      Cocci lung stain A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/57/6040\" title=\"picture 1B\">",
"      Cocci lung stain B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/26/30117\" title=\"picture 1C\">",
"      Cocci lung stain C",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17271?source=related_link\">",
"      Coccidioidal meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=related_link\">",
"      Coccidioidomycosis in compromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=related_link\">",
"      Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=related_link\">",
"      Diagnosis and treatment of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39734?source=related_link\">",
"      Management of pulmonary sequelae and complications of coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=related_link\">",
"      Manifestations and treatment of extrapulmonary coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/19/13617?source=related_link\">",
"      Patient information: Valley Fever (coccidioidomycosis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_27_13752="Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot";
var content_f13_27_13752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/27/13752/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13752/contributors\">",
"     Thomas Doyle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13752/contributors\">",
"     Ann Kavanaugh-McHugh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13752/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/27/13752/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13752/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13752/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/27/13752/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13752/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/27/13752/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9475669\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1888, Etienne-Louis Arthur Fallot described three cyanotic patients with four similar anatomic features (",
"    <a class=\"graphic graphic_figure graphicRef82493 \" href=\"UTD.htm?39/35/40501\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stenosis of the pulmonary artery",
"     </li>",
"     <li>",
"      Intraventricular communication",
"     </li>",
"     <li>",
"      Deviation of the origin of the aorta to the right",
"     </li>",
"     <li>",
"      Concentric right ventricular hypertrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This constellation of findings has since become known as tetralogy of Fallot (TOF).",
"   </p>",
"   <p>",
"    The pathophysiology, clinical features, and diagnosis of TOF will be reviewed here. An overview of the management of this disorder, including postoperative complications and issues related to pregnancy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=see_link\">",
"     \"Overview of the management of tetralogy of Fallot\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86987925\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of TOF in the United States is about 3.9 per 10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/2\">",
"     2",
"    </a>",
"    ]. This defect accounts for about 7 to 10 percent of cases of congenital heart disease and is one of the most common congenital heart lesions requiring intervention in the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/3\">",
"     3",
"    </a>",
"    ]. TOF occurs equally in males and females [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact embryologic abnormality that accounts for TOF is unknown. What is recognized is that during development, there is anterior and cephalad deviation of the infundibular septum. This results in a malaligned ventricular septal defect (VSD), with the aortic root overriding the defect and leading to subsequent right ventricular outflow obstruction (",
"    <a class=\"graphic graphic_figure graphicRef82493 \" href=\"UTD.htm?39/35/40501\">",
"     figure 1",
"    </a>",
"    ). The ensuing right ventricular hypertrophy is thought to be a response to the large VSD and right ventricular outflow obstruction with resultant systemic right ventricular systolic pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ventricular septal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VSD in TOF is most commonly a single large malaligned subaortic defect located in the perimembranous region of the septum (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52641 \" href=\"UTD.htm?35/53/36703\">",
"     image 1",
"    </a>",
"    ). The VSD can extend into the muscular septum. There are rarely other muscular ventricular septal defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=see_link\">",
"     \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Right ventricular outflow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The right ventricular outflow obstruction is often at multiple levels (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57537 \" href=\"UTD.htm?3/57/3984\">",
"     image 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The anterior and cephalad deviation of the infundibular septum results in subvalvar obstruction",
"     </li>",
"     <li>",
"      Hypertrophy of muscular bands in this region can further accentuate subvalvar obstruction",
"     </li>",
"     <li>",
"      The pulmonary valve annulus is usually hypoplastic, although in some instances it is of normal size",
"     </li>",
"     <li>",
"      The pulmonary valve itself is frequently bicuspid and stenotic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, it is not uncommon to identify an area of supravalvar narrowing in the main pulmonary artery at the sinotubular ridge. There may also be further obstruction at the branch pulmonary arteries. These may be diffusely hypoplastic or have focal areas of stenosis, most commonly at the proximal branch pulmonary arteries. The proximal left pulmonary artery near the site of ductal insertion is a frequent location for stenosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64416 graphicRef78255 \" href=\"UTD.htm?33/1/33811\">",
"     image 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overriding aorta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overriding aorta is a congenital anomaly, in which the aorta is displaced to the right over the VSD rather than the left ventricle. This results in blood flow from both ventricles into the aorta.",
"   </p>",
"   <p>",
"    The degree of aortic override of the VSD can vary widely and is one of the major factors used by some groups to differentiate between TOF and double outlet right ventricle. If one defines double outlet right ventricle as the presence of",
"    <span class=\"nowrap\">",
"     aortic/mitral",
"    </span>",
"    valve fibrous continuity, then the degree of override is not relevant to diagnosis. If, however, one defines double outlet right ventricle as a condition with greater than 50 percent aortic override, then, by definition, the degree of aortic override in TOF is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Associated cardiac features",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of frequently associated anatomic features that are important to look for when evaluating a patient with TOF, since they affect therapy. Associated cardiac anomalies occur in about 40 percent of patients with TOF.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 25 percent of patients have a right aortic arch. This is particularly important to identify if one is contemplating a palliative shunt.",
"     </li>",
"     <li>",
"      Abnormalities of the coronary arteries, such as the left anterior descending arising from the right coronary artery, are seen in about 9 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/5\">",
"       5",
"      </a>",
"      ]. These are important to identify prior to complete repair, since the course of the artery may run directly across the right ventricular outflow tract; inadvertent transection could have catastrophic consequences.",
"     </li>",
"     <li>",
"      Occasionally, patients have significant aorticopulmonary collateral vessels that may require attention prior to or at the time of surgery.",
"     </li>",
"     <li>",
"      A patent ductus arteriosus, multiple ventricular defects, and complete atrioventricular septal defects may be present.",
"     </li>",
"     <li>",
"      Infrequently, aortic valve regurgitation is present due to aortic cusp prolapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENETIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although TOF may present as part of a known syndrome, this lesion typically occurs sporadically without other anomalies.",
"   </p>",
"   <p>",
"    Surveys of patients with nonsyndromic TOF have reported the following genetic abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 114 patients with nonsyndromic TOF, 4 percent of patients had mutations in transcription factor NKX2.5., which appears to have a role in cardiac development [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In genome-wide surveys of patients with nonsyndromic TOF and their parents, de novo copy number variants were estimated to be present in about 10 percent of sporadic cases of TOF compared to less than 0.1 percent in controls at several chromosomal locations [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/7\">",
"       7",
"      </a>",
"      ].Several reports have associated TOF with mutations in TBX1 and ZFPM2 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/8-10\">",
"       8-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MTHFR polymorphism has also been associated with an increased risk of development of TOF [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further investigation is required to determine the role of these mutations and polymorphisms in the evolution of TOF.",
"   </p>",
"   <p>",
"    Approximately 15 percent of patients with TOF present with associated syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/8,12-18\">",
"     8,12-18",
"    </a>",
"    ] :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Down syndrome (trisomy 21).",
"     </li>",
"     <li>",
"      Alagille syndrome (mutations in JAG1). TOF as the sole manifestation of JAG1 mutations without other evidence of Alagille syndrome has also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link&amp;anchor=H29#H29\">",
"       \"Inherited disorders associated with conjugated hyperbilirubinemia\", section on 'Alagille syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      DiGeorge and velocardiofacial syndromes (deletion on chromosome 22q11). There may be susceptibility genes for TOF within the latter region of chromosome 22q11 in children without extracardiac anomalies [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/17,20,21\">",
"       17,20,21",
"      </a>",
"      ], and 22q11.2 deletion syndrome is unrecognized in many adult patients with TOF [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32343?source=see_link\">",
"       \"DiGeorge syndrome: Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic consequences of TOF are largely dependent upon the degree of right ventricular outflow obstruction. Since the VSD is typically large and unrestrictive, the pressure in the right ventricle reflects that of the left ventricle. As a result, the direction of blood flow across the VSD will be determined by the path of least resistance for blood flow, not by the size of the VSD. If the resistance to blood flow across the obstructed right ventricular outflow tract is less than the resistance to flow out of the aorta into the systemic circulation, blood will naturally shunt from the left ventricle to the right ventricle and into the pulmonary bed. In this situation, there is predominately a left-to-right shunt and the patient will be acyanotic.",
"   </p>",
"   <p>",
"    As the degree of right ventricular outflow obstruction increases, the resistance to blood flow into the pulmonary bed also increases. If the right ventricular obstruction is significant enough to increase resistance, it will be easier for blood to cross the VSD from the right ventricle into the left ventricle and go out the aorta, which now becomes the path of least resistance. This right-to-left shunt across the VSD will result in a large volume of desaturated blood entering the systemic circulation and cyanosis and polycythemia will ensue (",
"    <a class=\"graphic graphic_figure graphicRef82493 \" href=\"UTD.htm?39/35/40501\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One of the physiologic characteristics of TOF is that the right ventricular outflow obstruction can fluctuate. An individual with minimal cyanosis can develop a dynamic increase in right ventricular outflow tract obstruction with a subsequent increase in right-to-left shunt and the development of cyanosis. In the most dramatic situation, there can be near occlusion of the right ventricular outflow tract with profound cyanosis. These episodes are often referred to as \"tet spells\" or \"hypercyanotic spells\". The exact etiology of these episodes is unclear, although there have been a number of proposed mechanisms, including increased infundibular contractility, peripheral vasodilatation, hyperventilation, and stimulation of right ventricular mechanoreceptors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of the patient with TOF is dependent upon the degree of right ventricular outflow obstruction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with severe obstruction and inadequate pulmonary flow typically present in the immediate newborn period with profound cyanosis",
"     </li>",
"     <li>",
"      Children with moderate obstruction and balanced pulmonary and systemic flow may be noticed during elective evaluation for a murmur",
"     </li>",
"     <li>",
"      Children with minimal obstruction may present with pulmonary overcirculation and heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most children with this lesion are symptomatic and cyanotic; there is a subgroup, however, with typical morphology and hemodynamics that remains clinically asymptomatic for a period of time (pink variant). In general, the earlier the onset of systemic hypoxemia, the more likely it is that severe pulmonary outflow tract stenosis or atresia is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;On inspection, individuals with TOF are usually comfortable and in no distress. However, during hypercyanotic (tet) spells, they will become hyperpneic, and infants will often become agitated. If cyanosis is present, it is most easily seen in the nail beds and lips.",
"   </p>",
"   <p>",
"    On palpation, one may appreciate a prominent right ventricular impulse and occasionally a systolic thrill. Hepatomegaly is uncommon. Peripheral pulses are usually normal, although the presence of prominent pulses may suggest the existence of a significant patent ductus arteriosus or aorticopulmonary collaterals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cardiac auscultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;On auscultation, the first heart sound is normal, and the second heart sound is most commonly single because the pulmonic component is rarely audible. Third and fourth heart sounds are uncommon. An early systolic click along the left sternal border may be heard, which is thought to be due to flow into the dilated ascending aorta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Murmur",
"    </span>",
"    &nbsp;&mdash;&nbsp;The murmur in TOF is due primarily to the right ventricular outflow obstruction, not the VSD. The murmur is typically crescendo-decrescendo with a harsh systolic ejection quality; it is appreciated best along the left mid to upper sternal border with radiation posteriorly. It can, however, have a more regurgitant quality that can be easily mistaken for a VSD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The murmur is due both to the degree of obstruction and to the amount of flow across the obstruction. In TOF, unlike isolated valvar pulmonary stenosis, the amount of flow across the right ventricular outflow tract will decrease as the obstruction increases, due to the shunting of blood right-to-left across the VSD. Thus, as the obstruction increases, the murmur will become softer. During severe hypercyanotic (tet) spells, the murmur may actually disappear due to the markedly diminished flow across the obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of TOF is generally made by echocardiography. Other tests that are often performed during the evaluation of TOF include electrocardiogram and chest radiography. Findings from these studies are often suggestive but not conclusive for the diagnosis of TOF. Cardiac catheterization is sometimes needed to further delineate anatomy and hemodynamic changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two-dimensional echocardiography and Doppler examination allow assessment of all essential features of TOF and have a crucial role in diagnosis and preoperative evaluation. Complete echocardiographic evaluation may obviate the need for other imaging or diagnostic studies before surgical repair. Most of the information can be achieved with transthoracic echocardiography, but occasionally transesophageal echocardiography may be helpful for specific questions raised with transthoracic echocardiography. A complete study must address:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The location and number of VSDs",
"     </li>",
"     <li>",
"      The anatomy and severity of right ventricular outflow tract obstruction",
"     </li>",
"     <li>",
"      The coronary artery and aortic arch anatomy",
"     </li>",
"     <li>",
"      The presence of any associated anomalies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Ventricular septal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic large malaligned VSD must be evaluated in multiple views. The degree of aortic override can be best assessed in parasternal long axis and apical views (",
"    <a class=\"graphic graphic_movie graphicRef71450 \" href=\"UTD.htm?36/44/37569\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef79575 \" href=\"UTD.htm?14/57/15251\">",
"     movie 2",
"    </a>",
"    ). The extension of the defect from the membranous septum, beneath the tricuspid valve, and into the infracristal outlet septum is well seen in the parasternal short axis view; extension into the supracristal region, if present, can be seen in this view as well (",
"    <a class=\"graphic graphic_movie graphicRef73954 \" href=\"UTD.htm?42/16/43266\">",
"     movie 3",
"    </a>",
"    ). Potential extension of the defect posteriorly toward the inlet septum, or apically into the trabecular septum, can be examined in apical views; the transducer is swept through serial imaging planes from the more caudal views of the inlet septum to the anteriorly angulated views, showing the overriding aorta in continuity with both the mitral and tricuspid valves.",
"   </p>",
"   <p>",
"    The subcostal views are also helpful to delineate the bounds of the VSD, allowing particularly good representation of the relationship between the defect and the tricuspid and aortic valves. The subcostal right oblique view, obtained by rotating the transducer counterclockwise from the coronal views, is also helpful in identifying any potential extension of the defect into the supracristal region. In the rare cases of restrictive VSD in this lesion, this view also defines abnormal tricuspid valve attachments [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Right ventricular outflow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The multiple levels and severity of obstruction in the right ventricular outflow tract can also be evaluated by echocardiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53046 \" href=\"UTD.htm?16/22/16738\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef64797 \" href=\"UTD.htm?40/58/41889\">",
"     movie 4",
"    </a>",
"    ). Parasternal short axis and subcostal coronal and sagittal views allow the best examination of the infundibulum and pulmonary valve. These views demonstrate the anterior deviation of the conal septum and the infundibular muscle bundles that contribute to infundibular obstruction. The size of the usually hypoplastic pulmonary annulus can be assessed and compared to normal values for patient size and body surface area. This is important to establish the potential need for a transannular patch. The pulmonary valve may appear thickened and may dome in these views.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pulmonary arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The size and anatomy of the main pulmonary artery, the pulmonary arterial confluence, and the proximal branch pulmonary arteries can also be assessed in parasternal short axis views. The proximal branch pulmonary arteries should be assessed as far distally as possible in high parasternal views and in suprasternal notch long and short axis views, directing the transducer into the left and right chest (",
"    <a class=\"graphic graphic_movie graphicRef72460 \" href=\"UTD.htm?43/12/44226\">",
"     movie 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef51331 \" href=\"UTD.htm?27/50/28452\">",
"     movie 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Coronary arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximal coronary anatomy should be defined echocardiographically in patients with TOF. In addition to examining the coronary anatomy in the traditional short axis view, the examination should include sweeping the transducer anterior to the pulmonary outflow tract in parasternal long and short axis views (",
"    <a class=\"graphic graphic_movie graphicRef63092 \" href=\"UTD.htm?16/13/16593\">",
"     movie 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. This permits the identification of variations in coronary anatomy, including the origin of the left anterior descending from the right coronary artery or dual vessel supply to the anterior descending distribution; in these situations, coronary branches crossing anteriorly complicate the surgical approach to relief of right ventricular outflow tract obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Aortic arch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic arch situs and the branching patterns of the brachiocephalic arteries are defined in the suprasternal notch long and short axis views. Complete evaluation of the arch in these views is also important in delineating the presence of additional potential sources of pulmonary blood flow, including aorticopulmonary collaterals and a patent ductus arteriosus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=see_link\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Atrial and ventricular septa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echocardiographic evaluation of patients with TOF is completed by using both two dimensional imaging and color flow mapping of the atrial septum and ventricular septum in multiple imaging planes. This assessment defines additional atrial and ventricular septal defects and evaluates potential abnormalities of pulmonary and systemic venous return and the rare associated occurrence of left sided obstructive lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hemodynamic echocardiographic assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the large and generally unrestrictive defect in this lesion permits equalization of right and left ventricular pressures. The direction and degree of shunting is determined by the balance of resistance to flow into the systemic and pulmonary circulations and, to a large degree, by the severity of right ventricular outflow tract obstruction. The modified Bernoulli equation, applied to the peak flow velocity in the right ventricular outflow tract, can be used to calculate the outflow tract gradient:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     &Delta;P",
"    </span>",
"    &nbsp;= &nbsp;4V2",
"   </p>",
"   <p>",
"    Where",
"    <span class=\"nowrap\">",
"     &Delta;P",
"    </span>",
"    = peak pressure gradient between the right ventricle and the pulmonary artery (mmHg), V = velocity obtained by continuous wave Doppler interrogation of the right ventricular outflow tract. The pulmonary artery pressure can be estimated by subtracting this pressure gradient from the systemic blood pressure.",
"   </p>",
"   <p>",
"    While the modified Bernoulli equation is not valid in the setting of tunnel-like",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiple levels of obstruction, values obtained with this method correlate with those obtained in the cardiac catheterization laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/29\">",
"     29",
"    </a>",
"    ]. In practice, the contributions of the infundibulum value and branch pulmonary arteries cannot be separated by Doppler interrogation.",
"   </p>",
"   <p>",
"    In patients with minimal right ventricular outflow tract obstruction, the gradient across the right ventricular outflow tract will be low; the estimated pulmonary arterial pressure will be elevated; and shunting through the VSD, as assessed by pulsed Doppler and color flow mapping, will be predominantly left-to-right through much of the cardiac cycle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=see_link\">",
"     \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with a large left-to-right shunt, left atrial and left ventricular dilation may be apparent by two dimensional imaging. In patients with more severe right ventricular outflow tract obstruction, the estimated pulmonary artery pressure is normal, and pulsed Doppler and color flow mapping demonstrate increasing right-to-left shunting at the ventricular septal defect during the cardiac cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86988514\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG in TOF typically shows right atrial enlargement and right ventricular hypertrophy. Right axis deviation, prominent R waves anteriorly and S waves posteriorly, an upright (",
"    <a class=\"graphic graphic_waveform graphicRef81339 \" href=\"UTD.htm?39/33/40470\">",
"     waveform 1",
"    </a>",
"    ) T wave in V1 (after two days of life), and a qR pattern in the right sided chest leads may also be seen (",
"    <a class=\"graphic graphic_waveform graphicRef81339 \" href=\"UTD.htm?39/33/40470\">",
"     waveform 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27204?source=see_link\">",
"     \"ECG tutorial: Chamber enlargement and hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86988521\">",
"    <span class=\"h2\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic chest x-ray of a patient with TOF demonstrates a \"boot shaped\" heart with an upturned apex and a concave main pulmonary artery segment (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78997 \" href=\"UTD.htm?18/50/19232\">",
"     image 5",
"    </a>",
"    ). The heart size is often normal, and pulmonary flow will appear normal or decreased. A right aortic arch can be seen in 25 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although echocardiography can reveal the anatomy in many patients with TOF, cardiac catheterization may still be necessary to further delineate the structure. It is particularly helpful for assessing levels of right ventricular outflow obstruction, branch pulmonary artery stenosis or hypoplasia, coronary artery anatomy, presence of aorticopulmonary collaterals, and presence of accessory ventricular septal defects.",
"   </p>",
"   <p>",
"    The hemodynamic findings at catheterization typically reveal normal or only mildly elevated filling pressures. The left and right ventricular systolic pressures are equal and systemic due to the presence of the large VSD. Pulmonary artery pressures are normal or low. Saturations will indicate the degree of right-to-left shunting.",
"   </p>",
"   <p>",
"    Angiographic assessment should be geared toward the information that is needed; biplane angiography is ideal. A right ventricular injection will often adequately demonstrate the multiple levels of right ventricular obstruction as well as the anatomy of the branch pulmonary arteries (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57537 \" href=\"UTD.htm?3/57/3984\">",
"     image 2",
"    </a>",
"    ). This is typically done with the AP camera angled in a cranial and left anterior oblique projection, which allows better delineation of the branch pulmonary arteries. The lateral camera is kept in straight lateral projection, which provides excellent visualization of the infundibular and pulmonary valve anatomy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79323 \" href=\"UTD.htm?29/19/30015\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An aortic root injection will usually provide adequate identification of the coronary arteries, although selective injections may occasionally be needed. The coronary arteries usually are seen well with the AP camera in a right anterior oblique (RAO) projection and the lateral camera in a long axial oblique projection. The arch and descending aorta may also be seen in this view and provide evidence of the presence of a patent ductus arteriosus or collateral vessels. If collateral vessels are identified, selective injections are helpful to assess the areas of the pulmonary bed that they supply and whether they are the sole supply to these areas.",
"   </p>",
"   <p>",
"    The ventricular septal defect is best seen from a left ventricular injection in a long axial oblique projection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52641 \" href=\"UTD.htm?35/53/36703\">",
"     image 1",
"    </a>",
"    ). With the AP camera in an RAO projection, one will often also see the infundibular obstruction from left to right flow across the VSD (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63257 \" href=\"UTD.htm?24/63/25599\">",
"     image 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cardiac catheterization can also play a therapeutic role in some patients with TOF. Balloon valvuloplasty of the pulmonary valve can improve pulmonary flow in many children; there may also be an increase in pulmonary valve annulus size that may decrease the need for transannular patch repair [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13752/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/27/12727?source=see_link\">",
"     \"Natural history and treatment of pulmonic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/25/2450?source=see_link\">",
"       \"Patient information: Tetralogy of Fallot (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86987908\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetralogy of Fallot (TOF) is a cyanotic congenital heart disorder that encompasses four anatomic features: right ventricular hypertrophy, ventricular septal defect (VSD), overriding aorta, and right ventricular (RV) outflow obstruction. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, the prevalence of TOF is about 3.9 per 10,000 live births. TOF accounts for 7 to 10 percent of congenital heart disease. (See",
"      <a class=\"local\" href=\"#H86987925\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although TOF typically occurs sporadically without other anomalies, it can be present as part of a known syndrome or genetic disorder, such as Down syndrome. In addition, other associated cardiac anomalies occur in about 40 percent of patients with TOF. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Genetic factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Associated cardiac features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathophysiologic effects of TOF are largely dependent upon the degree of RV outflow obstruction. The direction of blood flow across the VSD is determined by the path of least resistance for blood flow and not by the size of the VSD. If the resistance to the RV outflow is lower than systemic resistance, then there is a predominant left-to-right flow, and the patient is not cyanotic. However, with significant RV obstruction, there will be a right-to-left shunt across the VSD, resulting in cyanosis (",
"      <a class=\"graphic graphic_figure graphicRef82493 \" href=\"UTD.htm?39/35/40501\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation is dependent on the degree of RV outflow obstruction and determines whether there is a left-to-right (acyanotic) or right-to-left shunt. In general, the earlier the onset of systemic hypoxemia, the more likely it is that severe pulmonary outflow tract stenosis or atresia is present. In addition to persistent cyanosis in severely affected patients, other findings include intermittent hypercyanotic (tet) spells, crescendo-decrescendo harsh systolic ejection murmur, and a single second heart sound. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of TOF is typically made by echocardiography, which can usually delineate the location and number of VSDs, the anatomy and severity of RV outflow tract obstruction, the coronary artery and aortic arch anatomy, the presence of any associated anomalies, and the hemodynamic abnormalities associated with the anatomical defects. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/1\">",
"      Fallot E. Contribution a l'anatomie pathologique de la maladie bleu (cyanose cardiaque). Mars Med 1888; 25:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Improved national prevalence estimates for 18 selected major birth defects--United States, 1999-2001. MMWR Morb Mortal Wkly Rep 2006; 54:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/3\">",
"      Report of the New England Regional Infant Cardiac Program. Pediatrics 1980; 65:375.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff JK. The Clinical Recognition of Congenital Heart Disease, 4th, WB Saunders, Philadelphia 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/5\">",
"      Dabizzi RP, Caprioli G, Aiazzi L, et al. Distribution and anomalies of coronary arteries in tetralogy of fallot. Circulation 1980; 61:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/6\">",
"      Goldmuntz E, Geiger E, Benson DW. NKX2.5 mutations in patients with tetralogy of fallot. Circulation 2001; 104:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/7\">",
"      Greenway SC, Pereira AC, Lin JC, et al. De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet 2009; 41:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/8\">",
"      Di Felice V, Zummo G. Tetralogy of fallot as a model to study cardiac progenitor cell migration and differentiation during heart development. Trends Cardiovasc Med 2009; 19:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/9\">",
"      Griffin HR, T&ouml;pf A, Glen E, et al. Systematic survey of variants in TBX1 in non-syndromic tetralogy of Fallot identifies a novel 57 base pair deletion that reduces transcriptional activity but finds no evidence for association with common variants. Heart 2010; 96:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/10\">",
"      Rauch R, Hofbeck M, Zweier C, et al. Comprehensive genotype-phenotype analysis in 230 patients with tetralogy of Fallot. J Med Genet 2010; 47:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/11\">",
"      Marinho C, Alho I, Guerra A, et al. The methylenetetrahydrofolate reductase gene variant (C677T) as a susceptibility gene for tetralogy of Fallot. Rev Port Cardiol 2009; 28:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/12\">",
"      Kramer HH, Majewski F, Trampisch HJ, et al. Malformation patterns in children with congenital heart disease. Am J Dis Child 1987; 141:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/13\">",
"      Freeman SB, Taft LF, Dooley KJ, et al. Population-based study of congenital heart defects in Down syndrome. Am J Med Genet 1998; 80:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/14\">",
"      Krantz ID, Smith R, Colliton RP, et al. Jagged1 mutations in patients ascertained with isolated congenital heart defects. Am J Med Genet 1999; 84:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/15\">",
"      Takahashi K, Kido S, Hoshino K, et al. Frequency of a 22q11 deletion in patients with conotruncal cardiac malformations: a prospective study. Eur J Pediatr 1995; 154:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/16\">",
"      Webber SA, Hatchwell E, Barber JC, et al. Importance of microdeletions of chromosomal region 22q11 as a cause of selected malformations of the ventricular outflow tracts and aortic arch: a three-year prospective study. J Pediatr 1996; 129:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/17\">",
"      Goldmuntz E, Clark BJ, Mitchell LE, et al. Frequency of 22q11 deletions in patients with conotruncal defects. J Am Coll Cardiol 1998; 32:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/18\">",
"      Lammer EJ, Chak JS, Iovannisci DM, et al. Chromosomal abnormalities among children born with conotruncal cardiac defects. Birth Defects Res A Clin Mol Teratol 2009; 85:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/19\">",
"      Bauer RC, Laney AO, Smith R, et al. Jagged1 (JAG1) mutations in patients with tetralogy of Fallot or pulmonic stenosis. Hum Mutat 2010; 31:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/20\">",
"      Kessler-Icekson G, Birk E, Weintraub AY, et al. Association of tetralogy of Fallot with a distinct region of del22q11.2. Am J Med Genet 2002; 107:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/21\">",
"      Bristow JD, Bernstein HS. Counseling families with chromosome 22q11 deletions: the catch in CATCH-22. J Am Coll Cardiol 1998; 32:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/22\">",
"      van Engelen K, Topf A, Keavney BD, et al. 22q11.2 Deletion Syndrome is under-recognised in adult patients with tetralogy of Fallot and pulmonary atresia. Heart 2010; 96:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/23\">",
"      Kothari SS. Mechanism of cyanotic spells in tetralogy of Fallot--the missing link? Int J Cardiol 1992; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/24\">",
"      Flanagan MF, Foran RB, Van Praagh R, et al. Tetralogy of Fallot with obstruction of the ventricular septal defect: spectrum of echocardiographic findings. J Am Coll Cardiol 1988; 11:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/25\">",
"      Musewe NN, Smallhorn JF, Moes CA, et al. Echocardiographic evaluation of obstructive mechanism of tetralogy of Fallot with restrictive ventricular septal defect. Am J Cardiol 1988; 61:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/26\">",
"      Berry JM Jr, Einzig S, Krabill KA, Bass JL. Evaluation of coronary artery anatomy in patients with tetralogy of Fallot by two-dimensional echocardiography. Circulation 1988; 78:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/27\">",
"      Caldwell RL, Ensing GJ. Coronary artery abnormalities in children. J Am Soc Echocardiogr 1989; 2:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/28\">",
"      Jureidini SB, Appleton RS, Nouri S. Detection of coronary artery abnormalities in tetralogy of Fallot by two-dimensional echocardiography. J Am Coll Cardiol 1989; 14:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/29\">",
"      Houston AB, Simpson IA, Sheldon CD, et al. Doppler ultrasound in the estimation of the severity of pulmonary infundibular stenosis in infants and children. Br Heart J 1986; 55:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/30\">",
"      Sreeram N, Saleem M, Jackson M, et al. Results of balloon pulmonary valvuloplasty as a palliative procedure in tetralogy of Fallot. J Am Coll Cardiol 1991; 18:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13752/abstract/31\">",
"      Massoud I, Imam A, Mabrouk A, et al. Palliative balloon valvoplasty of the pulmonary valve in tetralogy of Fallot. Cardiol Young 1999; 9:24.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5769 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13752=[""].join("\n");
var outline_f13_27_13752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H86987908\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9475669\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86987925\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ventricular septal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Right ventricular outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overriding aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Associated cardiac features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENETIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cardiac auscultation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Murmur",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Ventricular septal defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Right ventricular outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pulmonary arteries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Aortic arch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Atrial and ventricular septa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hemodynamic echocardiographic assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86988514\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86988521\">",
"      Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86987908\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5769\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5769|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/53/36703\" title=\"diagnostic image 1\">",
"      Tetralogy Fallot LV angiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/57/3984\" title=\"diagnostic image 2\">",
"      Tetralogy Fallot RV angiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/1/34847\" title=\"diagnostic image 3A\">",
"      Tetralogy Fallot PA angio I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/18/33071\" title=\"diagnostic image 3B\">",
"      Tetralogy Fallot PA angio II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/22/16738\" title=\"diagnostic image 4\">",
"      Subcostal coronal view tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/50/19232\" title=\"diagnostic image 5\">",
"      Chest xray tetralogy Fallot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/19/30015\" title=\"diagnostic image 6\">",
"      Lateral RV angiogram tetralogy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/63/25599\" title=\"diagnostic image 7\">",
"      RAO LV angiogram tetralogy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5769|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/35/40501\" title=\"figure 1\">",
"      Anatomy of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5769|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?36/44/37569\" title=\"movie 1\">",
"      Long axis tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?14/57/15251\" title=\"movie 2\">",
"      Long axis TOF VSD malalignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?42/16/43266\" title=\"movie 3\">",
"      Short axis tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/58/41889\" title=\"movie 4\">",
"      Subcostal view tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?43/12/44226\" title=\"movie 5\">",
"      Parasternal short axis view tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?27/50/28452\" title=\"movie 6\">",
"      Suprasternal color of Doppler TOF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?16/13/16593\" title=\"movie 7\">",
"      Short axis coronary artery TOF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5769|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?39/33/40470\" title=\"waveform 1\">",
"      ECG tetralogy of Fallot",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32343?source=related_link\">",
"      DiGeorge syndrome: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27204?source=related_link\">",
"      ECG tutorial: Chamber enlargement and hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=related_link\">",
"      Inherited disorders associated with conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/27/12727?source=related_link\">",
"      Natural history and treatment of pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=related_link\">",
"      Overview of the management of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=related_link\">",
"      Pathophysiology and clinical features of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/25/2450?source=related_link\">",
"      Patient information: Tetralogy of Fallot (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_27_13753="Tobramycin (systemic therapy and oral inhalation): Drug information";
var content_f13_27_13753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tobramycin (systemic therapy and oral inhalation): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/45/15061?source=see_link\">",
"    see \"Tobramycin (systemic therapy and oral inhalation): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/54/15209?source=see_link\">",
"    see \"Tobramycin (systemic therapy and oral inhalation): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9600299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9600303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      TOBI&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9600304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      TOBI&reg;;",
"     </li>",
"     <li>",
"      TOBI&reg; Podhaler&reg;;",
"     </li>",
"     <li>",
"      Tobramycin Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9601075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Aminoglycoside",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9600390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Individualization is",
"     <b>",
"      critical",
"     </b>",
"     because of the low therapeutic index.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Use of ideal body weight (IBW) for determining the mg/kg/dose appears to be more accurate than dosing on the basis of total body weight (TBW).",
"     </b>",
"     In morbid obesity, dosage requirement may best be estimated using a dosing weight of IBW + 0.4 (TBW - IBW).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Initial and periodic plasma drug levels (eg, peak and trough with conventional dosing) should be determined, particularly in critically-ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Severe life-threatening infections:",
"     </b>",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Conventional:",
"     </i>",
"     1-2.5 mg/kg/dose every 8-12 hours; to ensure adequate peak concentrations early in therapy, higher initial dosage may be considered in selected patients when extracellular water is increased (edema, septic shock, postsurgical, and/or trauma)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Once-daily:",
"     </i>",
"     4-7 mg/kg/dose once daily; some clinicians recommend this approach for all patients with normal renal function; this dose is at least as efficacious with similar, if not less, toxicity than conventional dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Brucellosis:",
"     </b>",
"     I.M., I.V.: 240 mg (I.M.) daily or 5 mg/kg (I.V.) daily for 7 days; either regimen recommended in combination with doxycycline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cholangitis:",
"     </b>",
"     I.M., I.V.: 4-6 mg/kg once daily with ampicillin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CNS shunt infection:",
"     </b>",
"     Intrathecal (unlabeled route): 5-20 mg/day (Tunkel, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cystic fibrosis:",
"     </b>",
"     Inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bethkis&reg;, TOBI&reg;: 300 mg every 12 hours (do not administer doses &lt;6 hours apart); administer in repeated cycles of 28 days on drug followed by 28 days off drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TOBI&reg; Podhaler&reg; (Canadian availability; not available in the U.S.): 112 mg (4 x 28 mg capsules) every 12 hours (do not administer doses &lt;6 hours apart); administer in repeated cycles of 28 days on drug followed by 28 days off drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diverticulitis, complicated:",
"     </b>",
"     I.M., I.V.: 1.5-2 mg/kg every 8 hours (with ampicillin and metronidazole)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infective endocarditis or synergy (for gram-positive infections):",
"     </b>",
"     I.M., I.V.: 1 mg/kg every 8 hours (with ampicillin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Meningitis",
"     </b>",
"     <b>",
"      <i>",
"       (Enterococcus or Pseudomonas aeruginosa)",
"      </i>",
"     </b>",
"     :  I.V.: 5 mg/kg/day in divided doses every 8 hours (administered with another bacteriocidal drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pelvic inflammatory disease:",
"     </b>",
"     I.M., I.V.: Loading dose: 2 mg/kg, then 1.5 mg/kg every 8 hours",
"     <b>",
"      or",
"     </b>",
"     4.5 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Plague",
"     </b>",
"     <b>",
"      <i>",
"       (Yersinia pestis):",
"      </i>",
"     </b>",
"     I.M., I.V.: Treatment: 5 mg/kg/day, followed by postexposure prophylaxis with doxycycline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pneumonia, hospital- or ventilator-associated:",
"     </b>",
"     I.M., I.V.: 7 mg/kg/day (with antipseudomonal beta-lactam or carbapenem)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against endocarditis (dental, oral, upper respiratory procedures, GI/GU procedures):",
"     </b>",
"     I.M., I.V.: 1.5 mg/kg with ampicillin (50 mg/kg) 30 minutes prior to procedure.",
"     <b>",
"      Note:",
"     </b>",
"     AHA guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tularemia:",
"     </b>",
"     I.M., I.V.: 5 mg/kg/day divided every 8 hours for 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infection:",
"     </b>",
"     I.M., I.V.: 1.5 mg/kg/dose every 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9600389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/54/15209?source=see_link\">",
"      see \"Tobramycin (systemic therapy and oral inhalation): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individualization is",
"     <b>",
"      critical",
"     </b>",
"     because of the low therapeutic index",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Use of ideal body weight (IBW) for determining the mg/kg/dose appears to be more accurate than dosing on the basis of total body weight (TBW).",
"     </b>",
"     In morbid obesity, dosage requirement may best be estimated using a dosing weight of IBW + 0.4 (TBW - IBW).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;5 years: 2.5 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;5 years: 2-2.5 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CNS shunt infection:",
"     </b>",
"     Intrathecal (unlabeled route): Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cystic fibrosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 2.5-3.3 mg/kg every 6-8 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Some patients may require larger or more frequent doses if serum levels document the need (eg, cystic fibrosis or febrile granulocytopenic patients).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation: Bethkis&reg;, TOBI&reg;, TOBI&reg; Podhaler&reg; (Canadian availability; not available in the U.S.): Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9600391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage should be based on an estimate of ideal body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M., I.V.: 1.5-5 mg/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Once daily or extended interval: 5-7 mg/kg/dose given every 24, 36, or 48 hours based on creatinine clearance",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9600392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       I.M., I.V.:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Conventional dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: Administer every 8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-60 mL/minute: Administer every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-40 mL/minute: Administer every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-20 mL/minute: Administer every 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 72 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     High-dose therapy: Interval may be extended (eg, every 48 hours) in patients with moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-59 mL/minute) and/or adjusted based on serum level determinations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days) (Heintz, 2009): Dialyzable (25% to 70%; variable; dependent on filter, duration, and type of HD): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose of  2-3 mg/kg, followed by:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild UTI or synergy: I.V.: 1 mg/kg every 48-72 hours; consider redosing for pre-HD or post-HD concentrations &lt;1mg/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate-to-severe UTI: I.V.: 1-1.5 mg/kg every 48-72 hours; consider redosing for pre-HD concentrations &lt;1.5-2 mg/L or post-HD concentrations &lt;1 mg/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Systemic gram-negative infection: I.V.: 1.5-2 mg/kg every 48-72 hours; consider redosing for pre-HD concentrations &lt;3-5 mg/L or post-HD concentrations &lt;2 mg/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Administration via peritoneal dialysis (PD) fluid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gram-negative infection: 4-8 mg/L (4-8 mcg/mL) of PD fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gram-positive infection (ie, synergy): 3-4 mg/L (3-4 mcg/mL) of PD fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Administration IVPB/I.M.: Dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute and follow levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005):  Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH/CVVHD/CVVHDF: I.V.: Loading dose of 2-3 mg/kg, followed by:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild UTI or synergy: I.V. 1 mg/kg every 24-36 hours (redose when  concentration &lt;1 mg/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate-severe UTI: I.V.: 1-1.5 mg/kg every 24-36 hours (redose when concentration &lt;1.5-2 mg/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Systemic gram-negative infection: I.V.: 1.5-2.5 mg/kg every 24-48 hours (redose when concentration &lt;3-5 mg/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Inhalation:",
"      </i>",
"     </b>",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9600393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      <i>",
"       I.M., I.V., Inhalation:",
"      </i>",
"     </b>",
"     No dosage adjustment necessary in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9600442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS: 80 mg (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1.2 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (2 mL); 40 mg/mL (2 mL, 30 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TOBI&reg;: 300 mg/5 mL (56s)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13164876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation [capsule]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TOBI&reg; Podhaler&reg;: 28 mg/capsule (224s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9600306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes solution for nebulization",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15390962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bethkis&reg;: FDA approved October 2012; availability is expected during the second or third quarter of 2013.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bethkis&reg; inhalation solution (300 mg/4 mL) is approved for the management of cystic fibrosis patients (&ge;6 years) with",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     TOBI&reg; Podhaler&trade;: FDA approved March 2013; availability anticipated in the second quarter of 2013.  Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9600395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Infuse over 30-60 minutes. Flush with saline before and after administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bethkis&reg;, TOBI&reg;: To be inhaled over ~15 minutes using a handheld reusable nebulizer (PARI-LC PLUS&trade;) with a PARI Vios air compressor (Bethkis&reg;) or a DeVilbiss&reg; Pulmo-Aide&reg; air compressor (TOBI&reg;). If multiple different nebulizer treatments are required, administer bronchodilator first, followed by chest physiotherapy, any other nebulized medications, and then TOBI&reg; or Bethkis&reg; last. Do not mix with other nebulizer medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TOBI&reg; Podhaler&reg; (Canadian availability; not available in the U.S.): Capsules should be administered by oral inhalation via Podhaler&reg; device following manufacturer recommendations for use and handling. Capsules should not be swallowed.  Patients requiring bronchodilator therapy should administer the bronchodilator 15-90 minutes prior to TOBI&reg; Podhaler&reg;. The sequence of chest physiotherapy and additional inhaled therapies is at the discretion of the healthcare provider however TOBI&reg; Podhaler&reg; should always be administered last.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy",
"     <i>",
"      in vivo",
"     </i>",
"     , particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9600361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 40 10% in dextrose, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, mannitol 20%, LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aldesleukin, alprostadil, amifostine, amiodarone, amsacrine, anidulafungin, aztreonam, bivalirudin, caspofungin, cefepime, ceftazidime, ciprofloxacin, cisatracurium, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, doripenem, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, foscarnet, furosemide, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, IL-2, insulin (regular), labetalol, linezolid, magnesium sulfate, melphalan, meperidine, midazolam, morphine, nicardipine, oxytocin, remifentanil, tacrolimus, telavancin, teniposide, theophylline, thiotepa, tigecycline, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, azithromycin, drotrecogin alfa, heparin, hetastarch in NS, indomethacin, pantoprazole, pemetrexed, piperacillin, piperacillin/tazobactam, propofol, sargramostim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Heparin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Diphenhydramine, doxapram.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Clindamycin, heparin, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9600307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of documented or suspected infections caused by susceptible gram-negative bacilli, including",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     . Tobramycin solution for inhalation and powder for inhalation (Canadian availability; not available in the U.S.) are  indicated for the management of cystic fibrosis patients with",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9600301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tobramycin may be confused with Trobicin&reg;, vancomycin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nebcin [Multiple international markets] may be confused with Naprosyn brand name for naproxen [U.S., Canada, and multiple international markets]; Nubain brand name for nalbuphine [Multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9600332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection:",
"     </b>",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion, disorientation, dizziness, fever, headache, lethargy, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Exfoliative dermatitis, itching, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Serum calcium, magnesium, potassium, and/or sodium decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, eosinophilia, granulocytopenia, leukocytosis, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, bilirubin increased, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain at the injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Hearing loss, tinnitus, ototoxicity (auditory), ototoxicity (vestibular), roaring in the ears",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased, cylindruria, serum creatinine increased, oliguria, proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Inhalation",
"     </b>",
"     (as reported for solution for inhalation unless otherwise noted):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gastrointestinal: Sputum discoloration (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Respiratory: FEV",
"     <sub>",
"      1",
"     </sub>",
"     decreased (2% to 31%), cough (22% [powder for inhalation]), rales (19%), voice alteration (6% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cardiovascular: Chest discomfort (3% [powder for inhalation])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Central nervous system: Malaise (6%), pyrexia (1% [powder for inhalation])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gastrointestinal: Abnormal taste (5% [powder for inhalation]), diarrhea (2%), xerostomia (2% [powder for inhalation])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hematologic: RBC sedimentation rate increased (8%), eosinophilia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Otic: Tinnitus (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Respiratory: Wheezing (5%), dyspnea (4% [powder for inhalation]), oropharyngeal pain (4% [powder for inhalation]), bronchitis (3%), epistaxis (3%), pharyngolaryngeal pain (3%), throat irritation (3% [powder for inhalation]), pulmonary function decreased (2% to 16%), rhinitis (2%), tonsillitis (2%), bronchospasm (1% [powder for inhalation]), upper respiratory tract infection (1% [powder for inhalation])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Miscellaneous: Immunoglobulins increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aphonia, bronchial secretions increased, deafness, exercise tolerance decreased, hearing loss, hypersensitivity (allergic reactions), hypoesthesia (oral), lower respiratory tract infection, musculoskeletal chest pain, nasal congestion, obstructive airway disorder, oral candidiasis, pneumonitis, pruritus, pulmonary congestion, rash, respiratory sounds abnormal, serum glucose increased, urticaria, vital capacity decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9600328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tobramycin, other aminoglycosides, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9600329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause nephrotoxicity;",
"     </b>",
"     usual risk factors include pre-existing renal impairment, concomitant nephrotoxic medications, advanced age, and dehydration. Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular blockade and respiratory paralysis: May cause neuromuscular blockade and respiratory paralysis, especially when given soon after anesthesia or muscle relaxants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause neurotoxicity;",
"     </b>",
"     usual risk factors include pre-existing renal impairment, concomitant neuro-/nephrotoxic medications, advanced age, and dehydration. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage. Discontinue treatment if signs of ototoxicity occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hearing impairment: Use with caution in patients with pre-existing vertigo, tinnitus, or hearing loss.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis and Parkinson&rsquo;s disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with pre-existing renal insufficiency; dosage modification required during systemic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warnings]: Aminoglycosides may cause fetal harm if administered to a pregnant woman.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Solution for inhalation: Bronchospasm may occur with tobramycin inhalation; bronchospasm or wheezing should be treated appropriately if either arise. Safety and efficacy have not been demonstrated in patients with FEV",
"     <sub>",
"      1",
"     </sub>",
"     &lt;40% or &gt;80% predicted (Bethkis&reg;, TOBI&reg;), or in patients colonized with",
"     <i>",
"      Burkholderia cepacia",
"     </i>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfite: Solution for injection may contain sodium metabisulfate; use caution in patients with sulfite allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term use: Systemic therapy is not intended for long-term therapy due to toxic hazards associated with extended administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9600351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9600308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9600309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Aminoglycosides may cause fetal harm if administered to a pregnant woman.",
"     </b>",
"     There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy; therefore, tobramycin is classified as pregnancy category D. Tobramycin crosses the placenta and produces detectable serum levels in the fetus. Although serious side effects to the fetus have not been reported following maternal use of tobramycin, a potential for harm exists.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of tobramycin may be altered. Pregnant women have an average-to-larger volume of distribution which may result in lower serum peak levels than for the same dose in nonpregnant women. Serum half-life is also shorter.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9600312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9600327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tobramycin is excreted into breast milk and breast-feeding is not recommended by the manufacturer; however, tobramycin is not well absorbed when taken orally. This limited oral absorption may minimize exposure to the nursing infant. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9600394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May require supplementation of calcium, magnesium, potassium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9600444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (Tobi Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/5 mL (5 mL): $143.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tobramycin Sulfate in Saline Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.8 mg/mL 0.9% (100 mL): $11.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.2 mg/mL 0.9% (50 mL): $10.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tobramycin Sulfate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.2 g/30 mL (30 mL): $26.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 gm/50 mL (50 mL): $28.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (2 mL): $3.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/2 mL (2 mL): $2.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Tobramycin Sulfate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.2 g (1): $93.24",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9600413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinalysis, urine output, BUN, serum creatinine, peak and trough plasma tobramycin levels. Levels are typically obtained after the third dose in conventional dosing. Be alert to ototoxicity; hearing should be tested before and during treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Some penicillin derivatives may accelerate the degradation of aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This may be clinically-significant for certain penicillin (ticarcillin, piperacillin, carbenicillin) and aminoglycoside (gentamicin, tobramycin) combination therapy in patients with significant renal impairment. Close monitoring of aminoglycoside levels is warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Inhalation: The utility of monitoring serum concentrations in patients with renal impairment should be per physician discretion; serum concentrations achieved following inhalation are significantly less than those achieved following parenteral therapy in patients with normal renal function.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F9600364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Timing of serum samples: Draw peak 30 minutes after 30-minute infusion has been completed or 1 hour following I.M. injection or beginning of infusion; draw trough immediately before next dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Serious infections: 6-8 mcg/mL (SI: 12-17 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Life-threatening infections: 8-10 mcg/mL (SI: 17-21 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Urinary tract infections: 4-6 mcg/mL (SI: 7-12 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Synergy against gram-positive organisms: 3-5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trough:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Serious infections: 0.5-1 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Life-threatening infections: 1-2 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     The American Thoracic Society (ATS) recommends trough levels of &lt;1 mcg/mL for patients with hospital-acquired pneumonia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Monitor serum creatinine and urine output; obtain drug levels after the third dose unless otherwise directed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation: Serum levels are ~1 mcg/mL one hour following a 300 mg dose in patients with normal renal function.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bramitob (CO, CZ, GB, IE);",
"     </li>",
"     <li>",
"      Brulamycin (HN);",
"     </li>",
"     <li>",
"      Nebcin (AU, BF, BG, BJ, CI, ET, GH, GM, GN, GR, KE, LR, MA, ML, MR, MU, MW, NE, NG, PK, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Nebcina (NO, SE);",
"     </li>",
"     <li>",
"      Nebcine (FR);",
"     </li>",
"     <li>",
"      Nebicina (IT);",
"     </li>",
"     <li>",
"      Obracin (BE, CH, NL);",
"     </li>",
"     <li>",
"      Rui Nuo Sai (CL);",
"     </li>",
"     <li>",
"      Tobi (AR, AT, BE, CH, CZ, DK, FR, GB, GR, HN, IE, IL, IT, NL, NO, PE, PL, PY, SE, TW);",
"     </li>",
"     <li>",
"      Tobra-gobens (DO);",
"     </li>",
"     <li>",
"      Tobramina (BR);",
"     </li>",
"     <li>",
"      Tobraneg (IN);",
"     </li>",
"     <li>",
"      Tobrasix (AT);",
"     </li>",
"     <li>",
"      Tronamycin (KP);",
"     </li>",
"     <li>",
"      Zoteon (CN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9600362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits, resulting in a defective bacterial cell membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9600365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Poorly absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation: Peak serum concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Solution for inhalation: ~1 mcg/mL following a 300 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Powder for inhalation: ~1 mcg/mL (range: 0.49-1.55 mcg/mL) following a 112 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.2-0.3 L/kg; Pediatrics: 0.2-0.7 L/kg; to extracellular fluid, including serum, abscesses, ascitic, pericardial, pleural, synovial, lymphatic, and peritoneal fluids; poor penetration into CSF, eye, bone, prostate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation: Tobramycin remains concentrated primarily in the airways",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: &le;1200 g: 11 hours; &gt;1200 g: 2-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: I.V.: 2-3 hours; directly dependent upon glomerular filtration rate; Inhalation: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with impaired renal function: 5-70 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 30-60 minutes; I.V.: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Normal renal function: Urine (~90% to 95%) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society and Infectious Diseases Society of America, &ldquo;Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2005, 171(4):388-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/15699079/pubmed\" id=\"15699079\" target=\"_blank\">",
"        15699079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bauer LA and Blouin RA, &ldquo;Influence of Age on Tobramycin. Pharmacokinetics in Patients With Normal Renal Function,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1981, 20:587-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/7325627/pubmed\" id=\"7325627\" target=\"_blank\">",
"        7325627",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow MS, Quintiliani, and Nightingale CH, \"",
"      <i>",
"       In Vivo",
"      </i>",
"      Inactivation of Tobramycin by Ticarcillin. A Case Report,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1982, 247(5):658-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/6798229/pubmed\" id=\"6798229\" target=\"_blank\">",
"        6798229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daly JS, Dodge RA, Glew RH, et al, \"Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 1997, 17(1):42-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/9069064/pubmed\" id=\"9069064\" target=\"_blank\">",
"        9069064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dowell JA, Korth-Bradley J, Milisci M, et al, \"Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2001, 41:979-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/11549103/pubmed\" id=\"11549103\" target=\"_blank\">",
"        11549103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farchione LA, \"Inactivation of Aminoglycosides by Penicillins,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1982, 8(Suppl A):27-36.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuchs PC, Stickel S, Anderson PH, et al, \"",
"      <i>",
"       In Vitro",
"      </i>",
"      Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(1):182-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/2014975/pubmed\" id=\"2014975\" target=\"_blank\">",
"        2014975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilbert DN, &ldquo;Once-Daily Aminoglycoside Therapy,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(3):399-405.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/2039189/pubmed\" id=\"2039189\" target=\"_blank\">",
"        2039189",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green TP, Mirkin BL, Peterson PK, et al, &ldquo;Tobramycin Serum Level Monitoring in Young Patients With Normal Renal Function,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1984, 9(5):457-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/6499344/pubmed\" id=\"6499344\" target=\"_blank\">",
"        6499344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Halstenson CE, Wong MO, Herman CS, et al, \"Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1992, 36(9):1832-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/1416875/pubmed\" id=\"1416875\" target=\"_blank\">",
"        1416875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hitt CM, Patel KB, Nicolau DP, et al, \"Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(23):2704-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/9408514/pubmed\" id=\"9408514\" target=\"_blank\">",
"        9408514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hustinx WN and Hoepelman IM, &ldquo;Aminoglycoside Dosage Regimens. Is Once a Day Enough?&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1993, 25(6):427-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/8119044/pubmed\" id=\"8119044\" target=\"_blank\">",
"        8119044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaffe G, Meyers BR, and Hirschman SZ, &ldquo;Pharmacokinetics of Tobramycin in Patients With Stable Renal Impairment, Patients Undergoing Peritoneal Dialysis, and Patients on Chronic Hemodialysis,&rdquo;",
"      <i>",
"       Antimicro Agents Chemother",
"      </i>",
"      , 1974, 5(6):611-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/15825414/pubmed\" id=\"15825414\" target=\"_blank\">",
"        15825414",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kahler DA, Schowengerdt KO, Fricker FJ, et al, &ldquo;Toxic Serum Trough Concentrations After Administration of Nebulized Tobramycin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(4):543-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/12680485/pubmed\" id=\"12680485\" target=\"_blank\">",
"        12680485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konishi H, Goto M, Nakamoto Y, et al, \"Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 23(5):653-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/6223576/pubmed\" id=\"6223576\" target=\"_blank\">",
"        6223576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau A, Lee M, Flascha S, et al, \"Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients with Normal Renal Function,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 24(4):533-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/6651279/pubmed\" id=\"6651279\" target=\"_blank\">",
"        6651279",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matzke GR, Jameson JJ, and Halstenson CE, &ldquo;Gentamicin Disposition in Young and Elderly Patients With Various Degrees of Renal Function,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1987, 27(3):216-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/3680577/pubmed\" id=\"3680577\" target=\"_blank\">",
"        3680577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayer PR, Brown CH, Carter RA, et al, &ldquo;Intramuscular Tobramycin Pharmacokinetics in Geriatric Patients,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1986, 20:611-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/3743420/pubmed\" id=\"3743420\" target=\"_blank\">",
"        3743420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCormack JP and Jewesson PJ, &ldquo;A Critical Re-evaluation of the &ldquo;Therapeutic Range&rdquo; of Aminoglycosides,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1992, 14(1):320-39.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nahata MC, Powell DA, Durrell DE, et al, &ldquo;Effect of Gestational Age and Birth Weight on Tobramycin Kinetics in Newborn Infants,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1984, 14(1):59-65.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nicolau DP, Freeman CD, Belliveau PP, et al, &ldquo;Experience With a Once-Daily Aminoglycoside Program Administered to 2184 Adult Patients,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1995, 39(3):650-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/7793867/pubmed\" id=\"7793867\" target=\"_blank\">",
"        7793867",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Preston SL and Briceland LL, &ldquo;Single Daily Dosing of Aminoglycosides,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1995, 15(3):297-316.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/7667165/pubmed\" id=\"7667165\" target=\"_blank\">",
"        7667165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramsey BW, Burns J, Smith A, et al, &ldquo;Safety and Efficacy of Tobramycin for Inhalation in Patients With Cystic Fibrosis: The Results of Two Phase III Placebo Controlled Clinical Trials,&rdquo;",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 1997, (Suppl 14):137-8, S10.3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramsey BW, Dorkin HL, Eisenberg JD, et al, &ldquo;Efficacy of Aerosolized Tobramycin in Patients With Cystic Fibrosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(24):1740-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/8497284/pubmed\" id=\"8497284\" target=\"_blank\">",
"        8497284",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russoe ME and Atkins-Thor E, \"Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,\"",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1981, 15(4):175-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/7237864/pubmed\" id=\"7237864\" target=\"_blank\">",
"        7237864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaw PK, Braun TL, Liebergen A, et al, &ldquo;Aerosolized Tobramycin Pharmacokinetics in Cystic Fibrosis Patients,&rdquo;",
"      <i>",
"       J Pediatr Pharm Pract",
"      </i>",
"      , 1997, 2(1):23-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith PF, Ballow CH, Booker BM, et al, \"Pharmacokinetics and Pharmacodynamics of Aztreonam and Tobramycin in Hospitalized Patients,\"",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2001, 23(8):1231-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/11558860/pubmed\" id=\"11558860\" target=\"_blank\">",
"        11558860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thompson MIB, Russo ME, Saxon BJ, et al, \"Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1982, 21(2):268-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/6462107/pubmed\" id=\"6462107\" target=\"_blank\">",
"        6462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Viollier AF, Standiford HC, Drusano GL, et al, \"Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1985, 15(5):597-606.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/4008387/pubmed\" id=\"4008387\" target=\"_blank\">",
"        4008387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walterspiel JN, Feldman S, Van R, et al, \"Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(9):1875-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/1952861/pubmed\" id=\"1952861\" target=\"_blank\">",
"        1952861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(15):1736-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zaske DE, Irvine P, Strand LM, et al, &ldquo;Wide Interpatient Variations in Gentamicin Dose Requirements for Geriatric Patients,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1982, 248(23):3122-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/27/13753/abstract-text/7143688/pubmed\" id=\"7143688\" target=\"_blank\">",
"        7143688",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9948 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-484BBBCA60-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13753=[""].join("\n");
var outline_f13_27_13753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600299\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600303\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600304\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9601075\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600390\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600389\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600391\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600392\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600393\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600442\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13164876\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600306\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15390962\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600395\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600361\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600307\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600301\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600332\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600328\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600329\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300149\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600351\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600308\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600309\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600312\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600327\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600394\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600444\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600413\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600364\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390239\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600362\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600365\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9948\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9948|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/20/41283?source=related_link\">",
"      Tobramycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/31/25076?source=related_link\">",
"      Tobramycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/59/35762?source=related_link\">",
"      Tobramycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/45/15061?source=related_link\">",
"      Tobramycin (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/54/15209?source=related_link\">",
"      Tobramycin (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_27_13754="Drugs and the liver: Metabolism and mechanisms of injury";
var content_f13_27_13754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drugs and the liver: Metabolism and mechanisms of injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/27/13754/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13754/contributors\">",
"     Anne M Larson, MD, FACP, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/27/13754/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13754/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/27/13754/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/27/13754/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/27/13754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatotoxicity can develop by a variety of mechanisms following the use of many drugs, both prescription and over-the-counter, herbal products, or toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A high index of suspicion is often necessary to expeditiously establish the diagnosis.",
"   </p>",
"   <p>",
"    The metabolism of drugs by the liver and the mechanisms by which drugs might injure the liver will be reviewed here. The different clinical patterns of drug-induced hepatotoxicity and the use of medications in patients with liver disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the management of chronic hepatitis C virus infection\", section on 'Dose adjustments of medications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\", section on 'Preventing superimposed insults'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced liver injury (also called DILI or drug-induced hepatotoxicity) is a well-recognized problem, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DILI accounts for up to 10 percent of all adverse drug reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/3-8\">",
"       3-8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The annual incidence of DILI with approved prescription medications when used at therapeutic doses is estimated to be between one in 10,000 to 100,000 persons exposed, but rates as high as 14 per 100,000 population have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/6-12\">",
"       6-12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DILI is the cause of illness in up to 30 percent of patients who present with acute hepatitis and represents up to 10 percent of consultations by hepatologists, and about 1 percent of all general medical admissions [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/6,13-16\">",
"       6,13-16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DILI is the cause of acute jaundice in up to 50 percent of patients with new onset jaundice, depending upon the patient population and geographic location [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/3,9,10,17-22\">",
"       3,9,10,17-22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DILI is also the most common cause of acute liver failure in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DILI is the most frequently cited reason for the withdrawal of medications from the marketplace [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/4,5,23,24\">",
"       4,5,23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Over 1000 medications and herbal products have been implicated in the development of DILI [",
"      <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H245315203\">",
"    <span class=\"h2\">",
"     Database of drugs, herbs, and supplements associated with hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"external\" href=\"file://www.livertox.nih.gov/\">",
"     searchable database",
"    </a>",
"    of drugs, herbal medications, and dietary supplements has been developed by the National Institutes of Health [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ROLE OF THE LIVER IN DRUG METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is responsible for concentrating, metabolizing, and eliminating the majority of drugs and toxins that are introduced into the body. While some parent drugs can directly cause hepatotoxicity, it is generally the metabolites of these compounds that lead to DILI. These compounds are processed by a variety of soluble and membrane-bound enzymes, especially those related to the hepatocyte endoplasmic reticulum. Each drug has its specific enzyme disposal pathway(s) of biotransformation involving one or more of these enzyme systems. Genetic variation in drug metabolism is increasingly being recognized as a factor in the development of DILI. Environmental factors (eg, alcohol use) may also alter the processing of drugs and toxins.",
"   </p>",
"   <p>",
"    Most processed drugs and toxins are then renally filtered or excreted in bile; both pathways require the drugs to be water soluble. The majority of oral drugs absorbed from the gastrointestinal tract are lipophilic and water-insoluble. They are rendered water-soluble via hepatic metabolism and thus more easily excreted. Exogenous products are hepatically metabolized predominantly through two mechanisms: phase I and phase II reactions (",
"    <a class=\"graphic graphic_figure graphicRef74094 \" href=\"UTD.htm?36/20/37198\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/28\">",
"     28",
"    </a>",
"    ]. The subsequent products are then excreted via excretory transporters on either the canalicular or sinusoidal membranes (phase III reactions) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Phase I reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;During phase I metabolism, polar groups are added to lipophilic molecules via oxidation, reduction, or hydrolysis to facilitate water-solubility. These reactions are catalyzed predominantly by the cytochrome P450 superfamily of mixed function oxidases (CYP) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. These membrane-bound hemoproteins are composed of an apoprotein and a heme prosthetic group (oxidizing center) and work in conjunction with NADPH.",
"   </p>",
"   <p>",
"    The CYP family contains over 50 proteins organized into 18 families (eg, CYP2) and 43 subfamilies (eg, CYP2E1) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/34\">",
"     34",
"    </a>",
"    ]. The vast majority of these enzymes are localized to the cytoplasmic side of the membrane of the endoplasmic reticulum (microsomal-type) or the mitochondria (mitochondrial type) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/34\">",
"     34",
"    </a>",
"    ]. The microsomal-type is responsible for phase I drug metabolism.",
"   </p>",
"   <p>",
"    Three families (CYP1, CYP2, and CYP3) are believed to be the most important for the hepatic metabolism of exogenous drugs and toxins, with a smaller contribution from CYP4 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/34-42\">",
"     34-42",
"    </a>",
"    ]. The remaining families are often highly specific for the metabolism of endogenous compounds and are not inducible by exogenous compounds [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/34,43\">",
"     34,43",
"    </a>",
"    ]. The most important drug metabolizing member is CYP3A4, comprising approximately 60 percent of all hepatic cytochromes and catalyzing the biotransformation of over 50 percent of commonly used drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/34,44\">",
"     34,44",
"    </a>",
"    ]. Free radicals and electrophilic compounds can be produced during this process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     CYP activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytochrome activity varies considerably depending in part upon the concentration of the enzymes and their degree of induction by exogenous factors (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Factors influencing drug metabolism and the risk of DILI'",
"    </a>",
"    below). Factors that alter the activity of an enzyme have the potential to increase the toxicity of a compound (either by reducing its conversion to nontoxic metabolites or by increasing its conversion to toxic metabolites) or to decrease its therapeutic effectiveness (eg, by increasing the rate of metabolism of active drug) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, alternate detoxification routes may become overloaded, leading to the development of hepatotoxicity. This may in part explain why some drugs (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ) are not toxic in normal therapeutic doses but are toxic when increased amounts are ingested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Phase II reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase II reactions conjugate the drug or its metabolite to a large water-soluble polar group, such as glucuronic acid, sulfate, acetate, glycine, glutathione, or a methyl group (",
"    <a class=\"graphic graphic_figure graphicRef74094 \" href=\"UTD.htm?36/20/37198\">",
"     figure 1",
"    </a>",
"    ). Following phase I metabolism, most compounds are still insufficiently hydrophilic for excretion and require further processing. As a general rule, phase II reactions result in the formation of readily excreted, nontoxic substances [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/28,40\">",
"     28,40",
"    </a>",
"    ]. These processes take place predominantly within the hepatocyte cytoplasm via the UDP-glucuronyl transferases (UGT1 and UGT2), sulfotransferases, and glutathione S-transferases. Glucuronidation and sulfation occur directly with the parent compound or with a metabolite formed by a phase I reaction. The effect of glucuronidation or sulfation is most commonly a decrease in pharmacologic activity with enhanced clearance of the compound (eg, acetaminophen, furosemide, and bilirubin). These enzymes are rarely responsible for toxic metabolite formation, and their nontoxic products are generally ready for excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/46\">",
"     46",
"    </a>",
"    ]. However, exceptions occur with specific drugs such as glucuronidation of morphine (which leads to increased analgesic potency) and sulfation of minoxidil (which is required for its antihypertensive effect).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Phase III reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase III reactions lead to the transport of drugs and drug-products into the bile. Biliary excretion is mediated by ATP-dependent transporters located in the bile canaliculi [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/47\">",
"     47",
"    </a>",
"    ]. These transporters are members of the adenosine triphosphate (ATP)-binding cassette (ABC) superfamily [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The predominant role of these transporters is that of regulation of bile formation and the excretion of xenobiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/49\">",
"     49",
"    </a>",
"    ]. Altered activity of these transporters can lead to hepatotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Factors influencing drug metabolism and the risk of DILI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors may alter the activity of any of these drug-metabolizing reactions and influence drug metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/50\">",
"     50",
"    </a>",
"    ]. Additionally, other factors may contribute to the risk of hepatotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118531904\">",
"    <span class=\"h3\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many genetic polymorphisms in the CYP isoenzymes and other drug-processing enzymes have been identified and associated with DILI [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/32,43,51-58\">",
"     32,43,51-58",
"    </a>",
"    ]. In addition, there is a strong association between certain HLA haplotypes and the development of DILI from medications such as flucloxacillin, ximelagatran, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/55,59-62\">",
"     55,59-62",
"    </a>",
"    ]. Genetic alterations may contribute to diminished metabolism, lack of metabolism, or excessive metabolism of a compound [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/63\">",
"     63",
"    </a>",
"    ]. This has been particularly well studied in the alcohol-metabolizing CYP2E1 subfamily and in the CYP2D6 subfamily, which is responsible for the metabolism of drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/1,64\">",
"     1,64",
"    </a>",
"    ]. This genetic variability may explain some of the individual hypersensitivity reactions to specific drugs.",
"   </p>",
"   <p>",
"    Genetic polymorphisms in the phase II and the phase III enzymes also lead to both decreased and increased activity. This is observed in glutathione s-transferases,",
"    <em>",
"     N",
"    </em>",
"    -acetyltransferase 2,",
"    <em>",
"    </em>",
"    and",
"    <em>",
"    </em>",
"    UDP-glucuronosyltransferases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/65-70\">",
"     65-70",
"    </a>",
"    ]. Certain genetic variations in the hepatobiliary transporters may also predispose to drug-induced cholestasis or injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. As an example, variable drug pharmacokinetics have been reported with digoxin and cyclosporine, depending upon which genetic variant of the phase III hepatobiliary enzyme was present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are features seen in idiosyncratic drug injury that suggest the injury is immune-mediated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. The regulation of the immune response is genetically determined, which may play a role in an individual's susceptibility to hepatotoxicity. In addition, genetic alterations in the hepatocytes themselves may contribute to risk of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4788380\">",
"    <span class=\"h3\">",
"     Alcohol ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of alcohol in the development of DILI remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Chronic alcohol ingestion increases CYP2E1 activity two-fold, an effect that lasts for up to 10 days following ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/78,80-84\">",
"     78,80-84",
"    </a>",
"    ]. Alcohol also inhibits the rate of glutathione synthesis, leading to accelerated glutathione turnover, and it impairs mitochondrial transport of glutathione (with sequestration within the mitochondria) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/78,80,85\">",
"     78,80,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drugs that have been reported to have increased hepatotoxicity when associated with alcohol intake are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    , cocaine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and vitamin A [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/86\">",
"     86",
"    </a>",
"    ]. Interestingly, a report from the US Drug-Induced Liver Injury Network found that any use of alcohol in the prior year was inversely associated with the seriousness of DILI [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, the role of alcohol in DILI remains incompletely understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1660400020\">",
"    <span class=\"h3\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction of CYP enzymes, particularly CYP1A2, has been observed with the ingestion of Brussels sprouts, cabbage, cruciferous vegetables (such as broccoli), and charcoal-broiled beef [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/34,87-89\">",
"     34,87-89",
"    </a>",
"    ]. In contrast, grapefruit juice inhibits CYP3A activity, primarily acting on the intestinal form of the enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. An excellent example is the interaction of grapefruit juice with the immunosuppressive agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    CYP activity may be increased by high protein diets and reduced by low protein diets and severe malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. Thus, states of severe malnutrition or chronic alcoholism with poor nutrition may influence certain detoxifying cofactors such as glutathione. Alternatively, obesity has been reported to increase the risk DILI in the setting of halothane use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Presence of other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concomitant use of two or more drugs may be one of the most important factors affecting components of the CYP system and influencing drug metabolism. A drug may either inhibit or enhance another drug's metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/34,97,98\">",
"     34,97,98",
"    </a>",
"    ]. The adage that \"alcohol and drugs do not mix\" is based in part upon this phenomenon.",
"   </p>",
"   <p>",
"    The list of drug interactions with CYP is vast and a complete treatise is beyond the scope of this review. The aryl hydrocarbons in cigarette smoke can induce CYP1A2 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/99\">",
"     99",
"    </a>",
"    ]. Competitive inhibition of CYP can lead to clinically important drug interactions which are most pronounced when there is no alternative pathway for the metabolism of a potentially toxic drug or its metabolite. The most spectacular example is the development of torsade de pointes during the administration of terfenadine or cisapride (both no longer available in the United States) to a patient taking a CYP3A4 inhibitor such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Drug-induced induction and inhibition of phase II enzymes are not uniformly seen. However, reduced phase II reactions have been described with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    use. There are many reports of both inhibition (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ) and induction (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , St. John's wort) of the phase III transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/48\">",
"     48",
"    </a>",
"    ]. These drug-drug interactions will significantly alter the transport and secretion activity of transport enzymes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Age and sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the frequency and severity of DILI increase with age, and women appear to be more susceptible than men [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/12,100\">",
"     12,100",
"    </a>",
"    ]. An overall decrease in CYP activity may develop with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. This has been observed with the metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , flucloxacillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/28,50\">",
"     28,50",
"    </a>",
"    ]. Metabolism by phase II enzymes does not appear to be altered by aging [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/101-103\">",
"     101-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants may show considerable immaturity of the supply of drug metabolizing CYP enzymes, which may be low to undetectable at birth and develop over time [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/104\">",
"     104",
"    </a>",
"    ]. There are also major differences in the activity of the phase II enzymes in children when compared with adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/104\">",
"     104",
"    </a>",
"    ]. Examples of medications that appear to have a greater risk of hepatotoxicity in children include acetylsalicylic acid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/50\">",
"     50",
"    </a>",
"    ]. There are no studies of the effects of aging on the hepatic phase III enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Underlying liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both acute and chronic liver diseases have a variable effect on the metabolism of many drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/105\">",
"     105",
"    </a>",
"    ]. Enzyme activities are generally reduced with increasing liver disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/105\">",
"     105",
"    </a>",
"    ]. As a result, CYP activity may be unaltered, reduced, or greatly reduced depending upon the severity of liver dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/35,105\">",
"     35,105",
"    </a>",
"    ]. The type of liver disease does not appear to be important.",
"   </p>",
"   <p>",
"    Phase II enzyme activity appears to be altered to a lesser degree [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/105-107\">",
"     105-107",
"    </a>",
"    ]. The presence of cholestasis leads to decreased secretion (phase III) of both endogenous and exogenous substances [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/105\">",
"     105",
"    </a>",
"    ]. This is seen not only in the setting of intrahepatic cholestasis but also secondary to biliary obstruction.",
"   </p>",
"   <p>",
"    There has been considerable concern about the safety of statins in the setting of chronic liver disease. However, there are now several trials that have confirmed their safety in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/12,108-111\">",
"     12,108-111",
"    </a>",
"    ]. However, there is more variation in serum levels of statins in the setting of cirrhosis; therefore, the drugs should be used more cautiously in this group [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/110\">",
"     110",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link&amp;anchor=H28#H28\">",
"     \"Statins: Actions, side effects, and administration\", section on 'Chronic liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data regarding the use of antituberculous agents or highly active antiretroviral therapy (HAART) are more conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/50,108,109,112-114\">",
"     50,108,109,112-114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=see_link\">",
"     \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"    </a>",
"    .) Patients with advanced liver disease who develop DILI are more likely to have a worse outcome due to decreased functional hepatic reserve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4788397\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe DILI rarely occurs from drugs taken at doses less than 10 mg, and drugs administered at daily doses of &ge;50 mg are significantly more likely to cause DILI. [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/50,74,115-119\">",
"     50,74,115-119",
"    </a>",
"    ]. In addition, compounds are more likely to cause DILI if they are extensively hepatically metabolized when compared with drugs that have less extensive metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/115,116,120\">",
"     115,116,120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MECHANISMS OF DRUG-INDUCED HEPATOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most toxic drug effects on the liver lead to hepatocyte necrosis or apoptosis and subsequent cell death. However, some drugs predominantly damage the bile ducts, export proteins or bile canaliculi (resulting in cholestasis), vascular endothelial cells (producing venoocclusive disease), or the stellate cells. There may also be mixed patterns of injury (",
"    <a class=\"graphic graphic_algorithm graphicRef74957 \" href=\"UTD.htm?26/5/26719\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/121\">",
"     121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Toxic hepatocellular injury may be classified based upon either clinical features (pattern of liver injury) or based upon the underlying pathogenic mechanism (intrinsic hepatotoxins versus idiosyncratic reactions) (",
"    <a class=\"graphic graphic_table graphicRef83839 \" href=\"UTD.htm?34/42/35499\">",
"     table 2",
"    </a>",
"    ). For the purposes of this review, we will use the pathogenic classification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intrinsic hepatotoxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrinsic hepatotoxins reproducibly and predictably cause dose-dependent hepatocellular necrosis (\"toxic\" hepatitis) in most mammalian species (",
"    <a class=\"graphic graphic_algorithm graphicRef74957 \" href=\"UTD.htm?26/5/26719\">",
"     algorithm 1",
"    </a>",
"    ). The latent period between the exposure and onset of hepatotoxicity is brief (ie, hours to a few days) and fairly consistent from person to person and among animal models. Serum aminotransferases are typically 8 to 500 times normal, while serum alkaline phosphatase levels are less elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/86\">",
"     86",
"    </a>",
"    ]. Mortality is high in severe cases. Although hepatocellular damage may be the primary effect, some of these compounds can also damage other organs (especially the kidneys). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link&amp;anchor=H1984922420#H1984922420\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\", section on 'Acute kidney injury (acute renal failure)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most instances, the drug itself or one of its active metabolites interacts with one or more intracellular constituents (eg, proteins, lipids, DNA) to produce a sequence of events that often results in cell death. Production of an active metabolite often yields free radicals, electrophilic radicals, or reactive oxygen species. Alternatively, covalent binding of the toxic metabolite to structures within the cell may interfere with their function or their regulation. These events may incite oxidative stress, glutathione depletion, redox changes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lipid peroxidation, which may further affect cellular functions (eg, mitochondria, endoplasmic reticulum, cytoskeleton, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/29,122,123\">",
"     29,122,123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drugs known to be intrinsically hepatotoxic are often removed from clinical use by regulatory agencies or fail to make it into the marketplace [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/24\">",
"     24",
"    </a>",
"    ]. Examples include carbon tetrachloride, chloroform, and tannic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/100\">",
"     100",
"    </a>",
"    ]. However, some drugs with intrinsic hepatotoxic potential are still used clinically, either because they show hepatotoxicity only in large doses (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , iron sulfate), or because they show known dose-related toxicity (eg, ethanol, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , L-asparaginase, and phosphorus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Idiosyncratic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cases of DILI are related to idiosyncratic reactions. These rare reactions occur in about 0.01 to 1 percent of individuals who are taking the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/29,122,124\">",
"     29,122,124",
"    </a>",
"    ]. The principal characteristic of this type of reaction is the apparent unpredictability of the liver injury in humans. The reactions tend to be species-specific and often cannot be reproduced experimentally in laboratory animals [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/122-125\">",
"     122-125",
"    </a>",
"    ]. The latent period between exposure to the drug and the sensitivity reaction is variable, although it is generally about one to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/76\">",
"     76",
"    </a>",
"    ]. A threshold dose may be required; drugs administered at doses of more than 50 mg daily are more likely to cause severe DILI when compared with dosing at &lt;10 mg daily [94].",
"   </p>",
"   <p>",
"    It is most likely the individual's response to the",
"    <span class=\"nowrap\">",
"     drug/metabolite",
"    </span>",
"    that determines the type of liver injury and the pathogenesis. Although the parent compound may directly lead to idiosyncratic DILI, it is most often a toxic metabolite that is at fault [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/122\">",
"     122",
"    </a>",
"    ]. Idiosyncratic drug toxicity may be either nonallergic (metabolic) or",
"    <span class=\"nowrap\">",
"     immunologic/allergic;",
"    </span>",
"    however, overlap likely exists [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/29,123,124\">",
"     29,123,124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In nonallergic injury, covalent binding of drug metabolites to cellular structures can incite cell death by disrupting critical cellular function. Immunologic idiosyncratic reactions depend upon a complex interaction of the drug and its metabolites with the host immune system, with resultant downstream effects that cause hepatocyte necrosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    apoptosis and unleash cytokines that can lead to secondary cell damage or have immune modulating effects [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/29,75\">",
"     29,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1660400127\">",
"    <span class=\"h3\">",
"     Metabolic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic DILI is probably due to genetically determined aberrant metabolism of the drug in susceptible patients. The duration of exposure before the development of toxicity varies from weeks to months, and reactions can develop several weeks after drug discontinuation. The disease recurs within many days to weeks after rechallenge. Features of hypersensitivity are absent. Drugs in this category include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"     disulfiram",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , troglitazone, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=see_link\">",
"     \"Isoniazid hepatotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been hypothesized that local accumulation of toxic metabolites results in covalent binding of the metabolite to cellular proteins, lipids, and DNA. The hepatocyte undergoes significant oxidative stress, leading to redox changes and lipid peroxidation, which results in cellular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/29,86\">",
"     29,86",
"    </a>",
"    ]. The function of cellular structures such as mitochondria, receptor signaling, microtubules, and the endoplasmic reticulum can also be directly affected [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. The drugs may also alter regulation of transporters that actively pump drug metabolites out of the hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/100\">",
"     100",
"    </a>",
"    ]. Immunologic injury may play some role in metabolic DILI. Neoantigens may be formed by the reaction of the metabolite with the hepatocyte, leading to activation of the immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1660400227\">",
"    <span class=\"h3\">",
"     Immunoallergic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoallergic DILI is the least well understood form of DILI, and the role of the immune system remains controversial. Immunoallergic DILI may be accompanied by clinical and histologic evidence of classic hypersensitivity. There is generally a delay in the onset of symptoms and the duration of exposure is generally about one to eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/122\">",
"     122",
"    </a>",
"    ]. Rash, fever, joint pain and inflammation, lymphadenopathy, eosinophilic leukocytosis and, in severe cases, the Stevens-Johnson syndrome may occur. However, these symptoms may be mild or absent. In some cases, the presentation may be similar to infectious mononucleosis (with atypical lymphocytes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .) There is a prompt recurrence of symptoms in response to drug rechallenge of one or two doses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/86,100,121\">",
"     86,100,121",
"    </a>",
"    ]. This type of injury is believed to be a metabolite-initiated, immune-mediated attack on the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial factor influencing drug-induced hypersensitivity appears to be the modification of \"self\" proteins due to covalent binding of the active metabolite with host tissues (haptenization). These drug-protein products (adducts) then behave as neoantigens [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/29,84,127\">",
"     29,84,127",
"    </a>",
"    ]. The neoantigens are then presented by major histocompatibility complex class II, which leads to the activation of helper T-lymphocytes that subsequently recruit cytotoxic T-lymphocytes, natural killer cells, and B-cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/29,74,121,124,128\">",
"     29,74,121,124,128",
"    </a>",
"    ]. Cytotoxic T-lymphocytes then mediate apoptosis via Fas ligand and granzyme",
"    <span class=\"nowrap\">",
"     B/porin",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Haptenization alone does not appear to trigger immune-mediated responses. The danger hypothesis has been proposed as an explanation for further injury. This hypothesis states that for the immune-mediated attack to develop, a second costimulatory factor must be present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/129\">",
"     129",
"    </a>",
"    ]. These factors appear to prime the immune system in susceptible individuals and may include infection or inflammatory conditions (eg, hepatitis B, hepatitis C, HIV infection), or hepatocyte stress [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/29,130,131\">",
"     29,130,131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neoantigens also prompt the development of autoantibodies against the cytochromes P450, which can be identified in the serum, although it is unclear if these participate in the immune attack [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/29,122,127,132\">",
"     29,122,127,132",
"    </a>",
"    ]. These autoantibodies are generally specific to the cytochrome that metabolizes the offending drug. The unique immunologic response of an individual to a drug and his or her specific T-cell receptor range may explain why hepatotoxicity occurs in some but not all individuals.",
"   </p>",
"   <p>",
"    The innate immune system may also participate. Hepatocyte necrosis appears to activate the innate system, most likely through proinflammatory mediators (eg, cytokines, chemokines, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/127,133\">",
"     127,133",
"    </a>",
"    ]. These mediators can be directly cytotoxic or lead to recruitment of cells of the innate immune system. The innate immune system may also have a role in recovery via antiinflammatory components [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/29,127\">",
"     29,127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, another factor influencing the individual response to drugs may be genetic polymorphisms of the major histocompatibility molecules (HLA), several of which have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/59-62,134\">",
"     59-62,134",
"    </a>",
"    ]. Certain HLA types may favor presentation of the offending drug. As an example, a predominance of HLA-DR6 is seen in hepatitis caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    , and a predominance of HLA-A11 is seen in hepatitis from tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/135\">",
"     135",
"    </a>",
"    ]. In one study, patients with HLA DRB1*5701 had an 80-fold increased risk of hepatotoxicity due to flucloxacillin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/60\">",
"     60",
"    </a>",
"    ]. There are also strong associations of hepatotoxicity with HLA DRB1*07 and the use of ximelagatran and with some HLA types and amoxicillin-clavulanate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Idiosyncratic drug reactions of this type are becoming more frequently recognized, and the list of drugs implicated is sizable (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    , dihydralazine, sulfonamides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    , halothane,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/100,136,137\">",
"     100,136,137",
"    </a>",
"    ]. Liver biopsy often reveals eosinophilic or granulomatous inflammation of the liver with hepatocyte necrosis and cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/27/13754/abstract/138,139\">",
"     138,139",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=see_link\">",
"     \"Sulfonamide allergy in non HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23651?source=see_link\">",
"       \"Patient information: Toxic hepatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1660400321\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although rare, drug-induced liver injury (DILI) accounts for up to 10 percent of all adverse drug reactions. The majority of patients will recover following withdrawal of the offending agent; however, in some cases DILI can be fatal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The liver is exposed to nearly all drugs absorbed from the intestinal tract and is the predominant site of drug metabolism. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Role of the liver in drug metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reactive drug metabolites, genetic susceptibility, and environmental factors all appear to play a role in development of DILI. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Mechanisms of drug-induced hepatotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiosyncratic hepatotoxicity is the most common type of DILI seen, accounting for &gt;90 to 95 percent of cases. However, our understanding of the pathogenesis of drug induced liver injury remains in its infancy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Idiosyncratic reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A",
"      <a class=\"external\" href=\"file://www.livertox.nih.gov/\">",
"       searchable database",
"      </a>",
"      of drugs, herbal medications, and dietary supplements has been developed by the National Institutes of Health.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113236795\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/1\">",
"      Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/2\">",
"      Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 2007; 25:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/3\">",
"      Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/4\">",
"      Ostapowicz G, Fontana RJ, Schi&oslash;dt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/5\">",
"      Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/6\">",
"      Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007; 11:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/7\">",
"      Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/8\">",
"      Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years experience. N Z Med J 1996; 109:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/9\">",
"      Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/10\">",
"      Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/11\">",
"      Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009; 29:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/12\">",
"      Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/13\">",
"      Galan MV, Potts JA, Silverman AL, Gordon SC. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected]. J Clin Gastroenterol 2005; 39:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/14\">",
"      De Valle MB, Av Klinteberg V, Alem N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006; 24:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/15\">",
"      D&oslash;ssing M, Andreasen PB. Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs. Scand J Gastroenterol 1982; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/16\">",
"      Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/17\">",
"      Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Curr Opin Gastroenterol 2008; 24:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/18\">",
"      Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol 2007; 102:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/19\">",
"      Akhtar AJ, Shaheen M. Jaundice in African-American and Hispanic patients with AIDS. J Natl Med Assoc 2007; 99:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/20\">",
"      Hussaini SH, O'Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol 2007; 19:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/21\">",
"      Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol 2007; 102:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/22\">",
"      Wai CT, Tan BH, Chan CL, et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 2007; 27:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/23\">",
"      Xu JJ, Diaz D, O'Brien PJ. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact 2004; 150:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/24\">",
"      Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/25\">",
"      Suzuki A, Andrade RJ, Bjornsson E, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010; 33:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/26\">",
"      Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs: an update. Swiss Med Wkly 2010; 140:w13080.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.livertox.nih.gov/ (Accessed on October 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/28\">",
"      Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995; 68:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/29\">",
"      Gunawan BK, Kaplowitz N. Mechanisms of drug-induced liver disease. Clin Liver Dis 2007; 11:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/30\">",
"      Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/31\">",
"      Peterson JA, Graham SE. A close family resemblance: the importance of structure in understanding cytochromes P450. Structure 1998; 6:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/32\">",
"      Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 1998; 28:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/33\">",
"      Werck-Reichhart D, Feyereisen R. Cytochromes P450: a success story. Genome Biol 2000; 1:REVIEWS3003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/34\">",
"      Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002; 3:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/35\">",
"      Ehrenpreis ED, Ehrenpreis S. Cytochrome P450: Role in drug-induced hepatotoxicity. Clin Liver Dis 1998; 2:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/36\">",
"      Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 1992; 21:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/37\">",
"      Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 1996; 24:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/38\">",
"      Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996; 24:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/39\">",
"      Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995; 15:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/40\">",
"      Murray M. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review). Int J Mol Med 1999; 3:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/41\">",
"      Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/42\">",
"      Lehmann DE. Enzymatic shunting: resolving the acetaminophen-warfarin controversy. Pharmacotherapy 2000; 20:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/43\">",
"      DeLeve LD, Kaplowitz N. Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am 1995; 24:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/44\">",
"      Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999; 369:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/45\">",
"      Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005; 35:325.",
"     </a>",
"    </li>",
"    <li>",
"     Nelson SD. Mechanisms of acetaminophen-induced liver disease. In: Drug-Induced Liver Disease, Kaplowitz N, DeLeve LD (Eds), Marcel Dekker, New York 2003. p.287.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/47\">",
"      Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008; 38:802.",
"     </a>",
"    </li>",
"    <li>",
"     Dean M. The human ATP-binding cassette (ABC) transporter superfamily. National Center for Biotechnology Information (NCBI), National Library of Medicine, Bethesda, MD, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/49\">",
"      Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006; 44:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/50\">",
"      Chalasani N, Bj&ouml;rnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010; 138:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/51\">",
"      Tanaka E. Update: genetic polymorphism of drug metabolizing enzymes in humans. J Clin Pharm Ther 1999; 24:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/52\">",
"      Hasler JA. Pharmacogenetics of cytochromes P450. Mol Aspects Med 1999; 20:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/53\">",
"      Dorne JL, Walton K, Renwick AG. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem Toxicol 2005; 43:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/54\">",
"      Pachkoria K, Lucena MI, Molokhia M, et al. Genetic and molecular factors in drug-induced liver injury: a review. Curr Drug Saf 2007; 2:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/55\">",
"      Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009; 29:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/56\">",
"      Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/57\">",
"      Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007; 47:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/58\">",
"      Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/59\">",
"      Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/60\">",
"      Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/61\">",
"      O'Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/62\">",
"      Andrade RJ, Lucena MI, Alonso A, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004; 39:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/63\">",
"      Ueshima Y, Tsutsumi M, Takase S, et al. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Alcohol Clin Exp Res 1996; 20:25A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/64\">",
"      Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/65\">",
"      Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/66\">",
"      Cho HJ, Koh WJ, Ryu YJ, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 2007; 87:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/67\">",
"      Possuelo LG, Castelan JA, de Brito TC, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008; 64:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/68\">",
"      Roy B, Chowdhury A, Kundu S, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001; 16:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/69\">",
"      Leiro V, Fern&aacute;ndez-Villar A, Valverde D, et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008; 28:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/70\">",
"      Lucena MI, Andrade RJ, Mart&iacute;nez C, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008; 48:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/71\">",
"      Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/72\">",
"      Choi JH, Ahn BM, Yi J, et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 2007; 17:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/73\">",
"      Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007; 17:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/74\">",
"      Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the \"danger hypothesis\" and innate immune system. Chem Res Toxicol 1999; 12:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/75\">",
"      Uetrecht J. Immune-mediated adverse drug reactions. Chem Res Toxicol 2009; 22:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/76\">",
"      Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis 2009; 29:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/77\">",
"      Strnad P, Zhou Q, Hanada S, et al. Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations. Gastroenterology 2010; 139:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/78\">",
"      Prescott LF. Paracetamol, alcohol and the liver. Br J Clin Pharmacol 2000; 49:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/79\">",
"      Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002; 40:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/80\">",
"      Schi&oslash;dt FV, Lee WM, Bondesen S, et al. Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. Aliment Pharmacol Ther 2002; 16:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/81\">",
"      Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/82\">",
"      Black M, Raucy J. Acetaminophen, alcohol, and cytochrome P-450. Ann Intern Med 1986; 104:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/83\">",
"      Perrot N, Nalpas B, Yang CS, Beaune PH. Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. Eur J Clin Invest 1989; 19:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/84\">",
"      Lucas D, M&eacute;nez C, Girre C, et al. Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. Alcohol Clin Exp Res 1995; 19:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/85\">",
"      Lauterburg BH, Velez ME. Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity. Gut 1988; 29:1153.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis JH. Medication-related and other forms of toxic liver injury. In: Clin Prac Gastroenterol, Brandt LJ (Ed), Churchill Livingstone, Philadelphia 1998. p.855.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/87\">",
"      Alvares AP, Pantuck EJ, Anderson KE, et al. Regulation of drug metabolism in man by environmental factors. Drug Metab Rev 1979; 9:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/88\">",
"      Pantuck EJ, Pantuck CB, Garland WA, et al. Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979; 25:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/89\">",
"      Hakooz N, Hamdan I. Effects of dietary broccoli on human in vivo caffeine metabolism: a pilot study on a group of Jordanian volunteers. Curr Drug Metab 2007; 8:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/90\">",
"      Dakovi��-Svajcer K, Samojlik I, Raskovi�� A, et al. The activity of liver oxidative enzymes after single and multiple grapefruit juice ingestion. Exp Toxicol Pathol 1999; 51:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/91\">",
"      Hukkanen J, Jacob P 3rd, Benowitz NL. Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. Clin Pharmacol Ther 2006; 80:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/92\">",
"      Brill S, Zimmermann C, Berger K, et al. In vitro interactions with repeated grapefruit juice administration--to peel or not to peel? Planta Med 2009; 75:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/93\">",
"      Zhang W, Parentau H, Greenly RL, et al. Effect of protein-calorie malnutrition on cytochromes P450 and glutathione S-transferase. Eur J Drug Metab Pharmacokinet 1999; 24:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/94\">",
"      Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994; 272:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/95\">",
"      Price VF, Miller MG, Jollow DJ. Mechanisms of fasting-induced potentiation of acetaminophen hepatotoxicity in the rat. Biochem Pharmacol 1987; 36:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/96\">",
"      Kurtovic J, Riordan SM. Paracetamol-induced hepatotoxicity at recommended dosage. J Intern Med 2003; 253:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/97\">",
"      Flockhart DA, Oesterheld JR. Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin N Am 2000; 9:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/98\">",
"      Kalgutkar AS, Obach RS, Maurer TS. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 2007; 8:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/99\">",
"      Poellinger L. Mechanistic aspects--the dioxin (aryl hydrocarbon) receptor. Food Addit Contam 2000; 17:261.",
"     </a>",
"    </li>",
"    <li>",
"     Shivakumar C, Farrell GC. Drug-induced liver disease. In: Schiff's Diseases of the Liver, Schiff ER, Maddrey WC, Sorrell MF (Eds), Wiley-Blackwell, Hoboken, NJ 2012. p.703.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/101\">",
"      Le Couteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998; 34:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/102\">",
"      Hilmer SN, Shenfield GM, Le Couteur DG. Clinical implications of changes in hepatic drug metabolism in older people. Ther Clin Risk Manag 2005; 1:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/103\">",
"      Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/104\">",
"      Benedetti MS, Whomsley R, Canning M. Drug metabolism in the paediatric population and in the elderly. Drug Discov Today 2007; 12:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/105\">",
"      Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/106\">",
"      Debinski HS, Lee CS, Danks JA, et al. Localization of uridine 5'-diphosphate-glucuronosyltransferase in human liver injury. Gastroenterology 1995; 108:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/107\">",
"      Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 2004; 5:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/108\">",
"      Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/109\">",
"      Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/110\">",
"      Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009; 29:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/111\">",
"      Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/112\">",
"      Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 41:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/113\">",
"      Cohen DE, Anania FA, Chalasani N, National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97:77C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/114\">",
"      Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006; 44:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/115\">",
"      Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/116\">",
"      Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/117\">",
"      Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009; 16:3041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/118\">",
"      Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009; 49:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/119\">",
"      Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004; 10:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/120\">",
"      Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010; 51:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/121\">",
"      Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J 2006; 8:E48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/122\">",
"      Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev 2004; 36:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/123\">",
"      Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002; 22:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/124\">",
"      Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/125\">",
"      Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/126\">",
"      Spielberg SP, Gordon GB, Blake DA, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981; 305:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/127\">",
"      Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/128\">",
"      Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/129\">",
"      Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/130\">",
"      Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/131\">",
"      Levy M. Role of viral infections in the induction of adverse drug reactions. Drug Saf 1997; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/132\">",
"      Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997; 26 Suppl 1:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/133\">",
"      Liu ZX, Kaplowitz N. Role of innate immunity in acetaminophen-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2006; 2:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/134\">",
"      Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26 Suppl 2:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/135\">",
"      Berson A, Fr&eacute;neaux E, Larrey D, et al. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol 1994; 20:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/136\">",
"      Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/137\">",
"      Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 1992; 33:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/138\">",
"      Kleckner HB, Yakulis V, Heller P. Letter: Severe hypersensitivity to diphenylhydantoin with circulating antibodies to the drug. Ann Intern Med 1975; 83:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/27/13754/abstract/139\">",
"      Pohl LR. Drug-induced allergic hepatitis. Semin Liver Dis 1990; 10:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3568 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-4DCBBA35C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13754=[""].join("\n");
var outline_f13_27_13754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1660400321\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H245315203\">",
"      Database of drugs, herbs, and supplements associated with hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ROLE OF THE LIVER IN DRUG METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Phase I reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - CYP activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Phase II reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Phase III reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Factors influencing drug metabolism and the risk of DILI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1118531904\">",
"      - Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4788380\">",
"      - Alcohol ingestion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1660400020\">",
"      - Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Presence of other drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Age and sex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Underlying liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4788397\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MECHANISMS OF DRUG-INDUCED HEPATOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intrinsic hepatotoxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Idiosyncratic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1660400127\">",
"      - Metabolic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1660400227\">",
"      - Immunoallergic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1660400321\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113236795\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3568\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3568|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/5/26719\" title=\"algorithm 1\">",
"      DILI hepatotoxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3568|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/20/37198\" title=\"figure 1\">",
"      Hepatic metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3568|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 1\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/42/35499\" title=\"table 2\">",
"      Classification of toxic hepatocellular injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=related_link\">",
"      Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=related_link\">",
"      Isoniazid hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23651?source=related_link\">",
"      Patient information: Toxic hepatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=related_link\">",
"      Sulfonamide allergy in non HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_27_13755="Health problems foster care";
var content_f13_27_13755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Health problems of children in foster care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Health problem",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of foster care population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic medical problem",
"       </td>",
"       <td>",
"        35 to 60 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medically fragile or complex",
"       </td>",
"       <td>",
"        11 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mental health problem",
"       </td>",
"       <td>",
"        80 percent of children older than age 4 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Developmental delay",
"       </td>",
"       <td>",
"        60 percent of children younger than age 5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Educational problems/special education",
"       </td>",
"       <td>",
"        45 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant dental disease",
"       </td>",
"       <td>",
"        35 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family relationship problems",
"       </td>",
"       <td>",
"        100 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13755=[""].join("\n");
var outline_f13_27_13755=null;
var title_f13_27_13756="Features DMD BMD";
var content_f13_27_13756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic, clinical, and pathologic features of Duchenne and Becker muscular dystrophies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Protein",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathology/ CPK",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Dystrophinopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Duchenne",
"       </td>",
"       <td>",
"        Xp21",
"       </td>",
"       <td>",
"        Dystrophin",
"       </td>",
"       <td>",
"        XR",
"       </td>",
"       <td>",
"        <p>",
"         Onset: 2-5 years",
"        </p>",
"        <p>",
"         Pseudohypertrophy",
"        </p>",
"        <p>",
"         Diminished IQ",
"        </p>",
"        <p>",
"         Cardiac involvement",
"        </p>",
"        <p>",
"         Rapid decline",
"        </p>",
"        <p>",
"         Death by age 20-30 years",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Severe dystrophic changes",
"        </p>",
"        <p>",
"         Absent dystrophin by immunohistochemistry",
"        </p>",
"        <p>",
"         Dystrophin &lt;5 percent of normal amount by Western blot",
"        </p>",
"        <p>",
"         Striking CK elevation early on",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intermediate \"outliers\"",
"       </td>",
"       <td>",
"        Xp21",
"       </td>",
"       <td>",
"        Dystrophin",
"       </td>",
"       <td>",
"        XR",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Dystrophin 5-20 percent normal amount by Western blot of muscle protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Becker",
"       </td>",
"       <td>",
"        Xp21",
"       </td>",
"       <td>",
"        Dystrophin",
"       </td>",
"       <td>",
"        XR",
"       </td>",
"       <td>",
"        <p>",
"         Onset: variable",
"        </p>",
"        <p>",
"         More benign course",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Less marked changes",
"        </p>",
"        <p>",
"         Reduced dystrophin by immunohistochemistry",
"        </p>",
"        <p>",
"         Normal or abnormal size dystrophin, amount &gt;20 percent by Western blot",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AD: autosomal dominant; AR: autosomal recessive; CK: creatine kinase; FKRP: fukutin related protein; TRIM32: tripartite motif containing gene 32; XR: X-linked recessive.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13756=[""].join("\n");
var outline_f13_27_13756=null;
var title_f13_27_13757="Viral meningitis epidemiology";
var content_f13_27_13757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epidemiologic, clinical data, and pathogenesis of common viruses causing meningitis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Virus",
"      </td>",
"      <td class=\"subtitle1\">",
"       Transmission",
"      </td>",
"      <td class=\"subtitle1\">",
"       Age",
"      </td>",
"      <td class=\"subtitle1\">",
"       Season",
"      </td>",
"      <td class=\"subtitle1\">",
"       Associated syndromes",
"      </td>",
"      <td class=\"subtitle1\">",
"       Frequency",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pathway to CNS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Piconavirus-enterovirus",
"      </td>",
"      <td rowspan=\"2\">",
"       <p>",
"        Person to person:",
"       </p>",
"       <p>",
"        Oral-fecal",
"       </p>",
"       <p>",
"        Inhalation",
"       </p>",
"      </td>",
"      <td rowspan=\"2\">",
"       <p>",
"        All ages",
"       </p>",
"       <p>",
"        More common in children",
"       </p>",
"      </td>",
"      <td rowspan=\"2\">",
"       <p>",
"        Summer",
"       </p>",
"       <p>",
"        Fall",
"       </p>",
"      </td>",
"      <td rowspan=\"2\">",
"       <p>",
"        Encephalitis",
"       </p>",
"       <p>",
"        Myocarditis",
"       </p>",
"       <p>",
"        Neonatal sepsis",
"       </p>",
"       <p>",
"        Poliomyelitis",
"       </p>",
"      </td>",
"      <td rowspan=\"2\">",
"       Common",
"      </td>",
"      <td rowspan=\"2\">",
"       Blood",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <p>",
"        Coxsackievirus",
"       </p>",
"       <p>",
"        Echovirus",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arboviruses",
"      </td>",
"      <td>",
"       <p>",
"        Direct inoculation by vectors:",
"       </p>",
"       <p>",
"        Mosquitoes",
"       </p>",
"       <p>",
"        Ticks",
"       </p>",
"      </td>",
"      <td>",
"       All ages",
"      </td>",
"      <td>",
"       <p>",
"        Summer",
"       </p>",
"       <p>",
"        Fall",
"       </p>",
"      </td>",
"      <td>",
"       Encephalitis",
"      </td>",
"      <td>",
"       Common",
"      </td>",
"      <td>",
"       Blood",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rabies",
"      </td>",
"      <td>",
"       Direct population by bite of a rabid animal, transplant or inhalation",
"      </td>",
"      <td>",
"       All ages",
"      </td>",
"      <td>",
"       No seasonal pattern",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Rare",
"      </td>",
"      <td>",
"       Neuronal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Influenza",
"      </td>",
"      <td>",
"       <p>",
"        Person to person:",
"       </p>",
"       <p>",
"        Inhalation",
"       </p>",
"      </td>",
"      <td>",
"       All ages",
"      </td>",
"      <td>",
"       Winter",
"      </td>",
"      <td>",
"       Encephalitis",
"      </td>",
"      <td>",
"       Infrequent",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Herpesviridae",
"      </td>",
"      <td>",
"       Person to person",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       No seasonal pattern",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Herpes simplex",
"      </td>",
"      <td>",
"       Vertical or horizontal",
"      </td>",
"      <td>",
"       More common in neonates",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Meningo-encephalitis",
"      </td>",
"      <td>",
"       Common",
"      </td>",
"      <td>",
"       <p>",
"        Blood",
"       </p>",
"       <p>",
"        Neuronal",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Varicella-zoster",
"      </td>",
"      <td>",
"       Respiratory",
"      </td>",
"      <td>",
"       Any age following primary infection",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Cerebellitus",
"       </p>",
"       <p>",
"        Encephalitis",
"       </p>",
"       <p>",
"        Myelitis",
"       </p>",
"      </td>",
"      <td>",
"       Infrequent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Epstein-Barr virus",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Encephalitis",
"       </p>",
"       <p>",
"        Myelitis",
"       </p>",
"       <p>",
"        Guillain-Barre",
"       </p>",
"      </td>",
"      <td>",
"       Rare",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Adenoviridae",
"      </td>",
"      <td rowspan=\"2\">",
"       Human",
"      </td>",
"      <td rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td rowspan=\"2\">",
"       No seasonal pattern",
"      </td>",
"      <td rowspan=\"2\">",
"       Encephalitis",
"      </td>",
"      <td rowspan=\"2\">",
"       Rare",
"      </td>",
"      <td rowspan=\"2\">",
"       Blood",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Adenovirus",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13757=[""].join("\n");
var outline_f13_27_13757=null;
var title_f13_27_13758="Substrate use in exercise";
var content_f13_27_13758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metabolic substrate utilization during exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 214px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Substrate utilization during prolonged exercise in normal subjects. Muscle glycogen breakdown is important initially but stores are rapidly depleted. Glucose (derived from circulating glucose and hepatic glycogenolysis and gluconeogenesis) and free fatty acids (FFA) then become increasingly important. However, the fall in plasma glucose concentration reduces the secretion of insulin and raises that of counterregulatory hormones (such as epinephrine and norepinephrine). As a result, prolonged exercise is associated with a gradual fall in utilization of glucose and increase in that of FFA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13758=[""].join("\n");
var outline_f13_27_13758=null;
var title_f13_27_13759="Risk of breast cancer with ERT";
var content_f13_27_13759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Breast cancer risk and hormone replacement therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 385px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relative risk of breast cancer according to the duration of use within categories of time since the last use of hormone replacement therapy. The relative risk (RR) of breast cancer in this analysis of data from 51 epidemiologic studies was highest among women who were current or recent (within five years) users of estrogen replacement therapy (ERT) and had the longest duration of use compared to never users. The RR of developing cancer was 1.35 for women who were current ERT users and had taken hormones for five years or longer.",
"    <div class=\"footnotes\">",
"     <br>",
"      * Relative to never-users, stratified by study, age at diagnosis, time since menopause, body-mass index, parity, and the age a woman was when her first child was born.",
"      <br>",
"       \"Last use within 5 years before diagnosis\" includes current users.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Collaborative Group on Hormonal Factors in Breast Cancer, Lancet 1997; 350:1047. Copyright &copy; The Lancet, Ltd. 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_27_13759=[""].join("\n");
var outline_f13_27_13759=null;
